
<!DOCTYPE html>
<html lang="en" >
    <head >

        <meta charset="UTF-8" />
        <meta http-equiv="X-UA-Compatible" content="IE=edge" />
        <meta name="HandheldFriendly" content="True" />
        <meta name="MobileOptimized" content="320" />
        <meta name="viewport" content="width=device-width, initial-scale=1.0" />

        
        

        
        
  <link rel="stylesheet" href="/static/assets/style-a68b4900.css" />
<script type="module" crossorigin="" src="/static/assets/base_style-0a3f24ce.js"></script>

  <link rel="stylesheet" href="/static/assets/style-ef962842.css" />
<link rel="stylesheet" href="/static/assets/style-3ade8b5c.css" />
<script type="module" crossorigin="" src="/static/assets/article_style-d757a0dd.js"></script>

  
  
    <style>
  
  
  @media screen and (min-width: 64em) {
    div.pmc-wm {
      background: repeat-y;
      background-image: url("data:image/svg+xml,%3Csvg xmlns='http://www.w3.org/2000/svg' width='20' height='350' xmlns:xlink='http://www.w3.org/1999/xlink'%3E%3Cdefs%3E%3Cfilter x='-.02' y='0' width='1.05' height='1' id='c'%3E%3CfeFlood flood-color='%23FFF'/%3E%3CfeComposite in='SourceGraphic'/%3E%3C/filter%3E%3Ctext id='b' font-family='Helvetica' font-size='11pt' style='opacity:1;fill:%23005ea2;stroke:none;text-anchor:middle' x='175' y='14'%3E%3C/text%3E%3Cpath id='a' style='fill:%23005ea2' d='M0 8h350v3H0z'/%3E%3C/defs%3E%3Cuse xlink:href='%23a' transform='rotate(90 10 10)'/%3E%3Cuse xlink:href='%23b' transform='rotate(90 10 10)' filter='url(%23c)'/%3E%3C/svg%3E");
      padding-left: 3rem;
    }
  }
</style>

  



        
            <link rel="apple-touch-icon"
                  sizes="180x180"
                  href="/static/img/favicons/apple-touch-icon.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="48x48"
                  href="/static/img/favicons/favicon-48x48.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="32x32"
                  href="/static/img/favicons/favicon-32x32.png" />
            <link rel="icon"
                  type="image/png"
                  sizes="16x16"
                  href="/static/img/favicons/favicon-16x16.png" />
            <link rel="manifest" href="/static/img/favicons/site.webmanifest" />
            <link rel="mask-icon"
                  href="/static/img/favicons/safari-pinned-tab.svg"
                  color="#0071bc" />
            <meta name="msapplication-config"
                  content="/static/img/favicons/browserconfig.xml" />
            <meta name="theme-color" content="#ffffff" />
        

        <title>
            Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective - PMC
        </title>

        
        
  
  <!-- Logging params: Pinger defaults -->
<meta name="ncbi_app" content="cloudpmc-viewer" />
<meta name="ncbi_db" content="pmc" />
<meta name="ncbi_phid" content="FF20814C89B732B31A814C002A187A7B.m_1" />
<meta name="ncbi_pinger_stat_url" content="https://pmc.ncbi.nlm.nih.gov/stat" />
<!-- Logging params: Pinger custom -->
<meta name="ncbi_pdid" content="article" />
  
    <link rel="preconnect" href="https://www.google-analytics.com" />

    
        <link rel="preconnect" href="https://cdn.ncbi.nlm.nih.gov" />
    

    <!-- Include USWDS Init Script -->
    <script src="/static/assets/uswds-init.js"></script>


    <meta name="ncbi_domain" content="jheor">
<meta name="ncbi_type" content="fulltext">
<meta name="ncbi_pcid" content="journal">
<meta name="ncbi_feature" content="associated_data">
<link rel="canonical" href="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333935/">
<meta name="robots" content="INDEX,NOFOLLOW,NOARCHIVE">
<meta name="citation_journal_title" content="Journal of Health Economics and Outcomes Research">
<meta name="citation_title" content="Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective">
<meta name="citation_author" content="Jas Bindra">
<meta name="citation_author_institution" content="Falcon Research Group, North Potomac, Maryland">
<meta name="citation_author" content="Ishveen Chopra">
<meta name="citation_author_institution" content="Manticore Consultancy, Bethesda, Maryland">
<meta name="citation_author" content="Kyle Hayes">
<meta name="citation_author_institution" content="Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey">
<meta name="citation_author" content="John Niewoehner">
<meta name="citation_author_institution" content="Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey">
<meta name="citation_author" content="Mary P Panaccio">
<meta name="citation_author_institution" content="Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey">
<meta name="citation_author" content="George J Wan">
<meta name="citation_author_institution" content="Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey">
<meta name="citation_publication_date" content="2025 Aug 6">
<meta name="citation_volume" content="12">
<meta name="citation_issue" content="2">
<meta name="citation_firstpage" content="50">
<meta name="citation_doi" content="10.36469/001c.142078">
<meta name="citation_pmid" content="40787087">
<meta name="citation_abstract_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333935/">
<meta name="citation_fulltext_html_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333935/">
<meta name="citation_pdf_url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333935/pdf/jheor_2025_12_2_142078.pdf">
<meta name="description" content="Background: Proteinuria, a critical marker of glomerulosclerosis, poses a challenge in idiopathic membranous nephropathy (iMN), particularly when standard treatments fail. Acthar® Gel, a US Food and Drug Administration–approved treatment option, may ...">
<meta name="og:title" content="Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective">
<meta name="og:type" content="article">
<meta name="og:site_name" content="PubMed Central (PMC)">
<meta name="og:description" content="Background: Proteinuria, a critical marker of glomerulosclerosis, poses a challenge in idiopathic membranous nephropathy (iMN), particularly when standard treatments fail. Acthar® Gel, a US Food and Drug Administration–approved treatment option, may ...">
<meta name="og:url" content="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333935/">
<meta name="og:image" content="https://cdn.ncbi.nlm.nih.gov/pmc/cms/images/pmc-card-share.jpg?_=0">
<meta name="twitter:card" content="summary_large_image">
<meta name="twitter:site" content="@ncbi">
    
    

    </head>
    <body >
        
    <a class="usa-skipnav " href="#main-content">
      Skip to main content
    </a>


        
            

<section class="usa-banner " aria-label="Official website of the United States government" >
    <div class="usa-accordion">
        <header class="usa-banner__header">
            <div class="usa-banner__inner">
                <div class="grid-col-auto">
                    <img aria-hidden="true"
                         class="usa-banner__header-flag"
                         src="/static/img/us_flag.svg"
                         alt="" />
                </div>

                <div class="grid-col-fill tablet:grid-col-auto" aria-hidden="true">
                    <p class="usa-banner__header-text">
                        An official website of the United States government
                    </p>
                    <span class="usa-banner__header-action">Here's how you know</span>
                </div>

                



















    
        <button
            type="button"
        
    
    class="usa-accordion__button usa-banner__button
           

           
               
               
               
               
            

           
           
           
           "
    aria-expanded="false"
    aria-controls="gov-banner-default"
    
    data-testid="storybook-django-banner"
    
    >
    
        

        
                    <span class="usa-banner__button-text">Here's how you know</span>
                

        
    
        
            </button>
        


            </div>
        </header>

        <div class="usa-banner__content usa-accordion__content"
             id="gov-banner-default"
             hidden>
            <div class="grid-row grid-gap-lg">
                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-dot-gov.svg"
                         alt=""
                         aria-hidden="true" />
                    <div class="usa-media-block__body">
                        <p>
                            <strong>Official websites use .gov</strong>
                            <br />
                            A
                            <strong>.gov</strong> website belongs to an official
                            government organization in the United States.
                        </p>
                    </div>
                </div>

                <div class="usa-banner__guidance tablet:grid-col-6">
                    <img class="usa-banner__icon usa-media-block__img"
                         src="/static/img/icon-https.svg"
                         alt=""
                         aria-hidden="true" />

                    <div class="usa-media-block__body">
                        <p>
                            <strong>Secure .gov websites use HTTPS</strong>
                            <br />
                            A <strong>lock</strong> (
                            <span class="icon-lock">
                                <svg xmlns="http://www.w3.org/2000/svg"
                                     width="52"
                                     height="64"
                                     viewBox="0 0 52 64"
                                     class="usa-banner__lock-image"
                                     role="graphics-symbol"
                                     aria-labelledby="banner-lock-description"
                                     focusable="false">
                                    <title id="banner-lock-title">Lock</title>
                                    <desc id="banner-lock-description">
                                    Locked padlock icon
                                    </desc>
                                    <path fill="#000000"
                                          fill-rule="evenodd"
                                          d="M26 0c10.493 0 19 8.507 19 19v9h3a4 4 0 0 1 4 4v28a4 4 0 0 1-4 4H4a4 4 0 0 1-4-4V32a4 4 0 0 1 4-4h3v-9C7 8.507 15.507 0 26 0zm0 8c-5.979 0-10.843 4.77-10.996 10.712L15 19v9h22v-9c0-6.075-4.925-11-11-11z" />
                                </svg>
</span>) or <strong>https://</strong> means you've safely
                                connected to the .gov website. Share sensitive
                                information only on official, secure websites.
                            </p>
                        </div>
                    </div>
                </div>
            </div>
        </div>
    </section>

        

        
    
    
    

<div class="usa-overlay">
</div>



<header class="usa-header usa-header--extended usa-header--wide" data-testid="header" data-header >
    <div class="ncbi-header">
        <div class="ncbi-header__container">
            
                <a class="ncbi-header__logo-container" href="https://www.ncbi.nlm.nih.gov/">
                    <img alt="
                                  NCBI home page
                              "
                         class="ncbi-header__logo-image"
                         src="/static/img/ncbi-logos/nih-nlm-ncbi--white.svg" />
                </a>
            

            <!-- Mobile menu hamburger button -->
            



















    
        <button
            type="button"
        
    
    class="usa-menu-btn ncbi-header__hamburger-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Show menu"
    data-testid="navMenuButton"
    
    >
    
        

        
                <svg aria-hidden="true"
                     class="ncbi-hamburger-icon"
                     fill="none"
                     focusable="false"
                     height="21"
                     viewBox="0 0 31 21"
                     width="31"
                     xmlns="http://www.w3.org/2000/svg">
                    <path clip-rule="evenodd"
                          d="M0.125 20.75H30.875V17.3333H0.125V20.75ZM0.125 12.2083H30.875V8.79167H0.125V12.2083ZM0.125 0.25V3.66667H30.875V0.25H0.125Z"
                          fill="#F1F1F1"
                          fill-rule="evenodd" />
                </svg>
            

        
    
        
            </button>
        



            
                <!-- Desktop buttons-->
                <div class="ncbi-header__desktop-buttons">
                    
                        <!-- Desktop search button -->
                        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button
           "
    aria-expanded="false"
    aria-controls="search-field-desktop-navigation"
    aria-label="Show search overlay"
    data-testid="toggleSearchPanelButton"
    data-toggle-search-panel-button
    >
    
        

        
                            


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#search" />
    </svg>


                            Search
                        

        
    
        
            </button>
        


                    

                    <!-- Desktop login dropdown -->
                    
                        <div class="ncbi-header__login-dropdown">
                            



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--unstyled ncbi-header__desktop-button ncbi-header__login-dropdown-button
           "
    aria-expanded="false"
    aria-controls="login-dropdown-menu"
    aria-label="Show login menu"
    data-testid="toggleLoginMenuDropdown"
    data-desktop-login-button
    >
    
        

        
                                


    <svg class="usa-icon " role="graphics-symbol" aria-hidden="true"    >
        
        <use xlink:href="/static/img/sprite.svg#person" />
    </svg>



                                <span data-login-dropdown-text>Log in</span>

                                <!-- Dropdown icon pointing up -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-less ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-up-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_less" />
    </svg>



                                <!-- Dropdown icon pointing down -->
                                


    <svg class="usa-icon ncbi-header__login-dropdown-icon ncbi-header__login-dropdown-icon--expand-more ncbi-header__login-dropdown-icon--hidden" role="graphics-symbol" aria-hidden="true"    data-login-dropdown-down-arrow>
        
        <use xlink:href="/static/img/sprite.svg#expand_more" />
    </svg>


                            

        
    
        
            </button>
        



                            <!-- Login dropdown menu -->
                            <ul class="usa-nav__submenu ncbi-header__login-dropdown-menu"
                                id="login-dropdown-menu"
                                data-desktop-login-menu-dropdown
                                hidden>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                                    </li>
                                
                                    <li class="usa-nav__submenu-item">
                                        <!-- Uses custom style overrides to render external and document links. -->
                                        








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                                    </li>
                                
                                <li class="usa-nav__submenu-item">
                                    



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           usa-button--outline ncbi-header__login-dropdown-logout-button
           "
    
    
    
    data-testid="desktopLogoutButton"
    data-desktop-logout-button
    >
    
        

        Log out

        
    
        
            </button>
        


                                </li>
                            </ul>
                        </div>
                    
                </div>
            
        </div>
    </div>

    <!-- Search panel -->
    
        <div class="ncbi-search-panel ncbi--show-only-at-desktop"
             data-testid="searchPanel"
             data-header-search-panel
             hidden>
            <div class="ncbi-search-panel__container">
                <form action="https://www.ncbi.nlm.nih.gov/search/all/"
                      aria-describedby="search-field-desktop-navigation-help-text"
                      autocomplete="off"
                      class="usa-search usa-search--big ncbi-search-panel__form"
                      data-testid="form"
                      method="GET"
                      role="search">
                    <label class="usa-sr-only"
                           data-testid="label"
                           for="search-field-desktop-navigation">
                        Search…
                    </label>
                    <input class="usa-input"
                           data-testid="textInput"
                           id="search-field-desktop-navigation"
                           name="term"
                           
                               placeholder="Search NCBI"
                           
                           type="search"
                           value="" />
                    



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    data-testid="button"
    
    >
    
        

        
                        <span class="usa-search__submit-text">
                            Search NCBI
                        </span>
                    

        
    
        
            </button>
        


                </form>

                
            </div>
        </div>
    

    <nav aria-label="Primary navigation" class="usa-nav">
        <p class="usa-sr-only" id="primary-navigation-sr-only-title">
            Primary site navigation
        </p>

        <!-- Mobile menu close button -->
        



















    
        <button
            type="button"
        
    
    class="usa-nav__close ncbi-nav__close-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    aria-label="Close navigation menu"
    data-testid="navCloseButton"
    
    >
    
        

        
            <img src="/static/img/usa-icons/close.svg" alt="Close" />
        

        
    
        
            </button>
        



        
            <!-- Mobile search component -->
            <form class="usa-search usa-search--small ncbi--hide-at-desktop margin-top-6"
                  role="search">
                <label class="usa-sr-only" for="search-field">
                    Search
                </label>

                <input class="usa-input"
                       id="search-field-mobile-navigation"
                       type="search"
                       
                           placeholder="Search NCBI"
                       
                       name="search" />

                



















    
        <button
            type="submit"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           
           "
    
    
    
    
    
    >
    
        

        
                    <!-- This SVG should be kept inline and not replaced with a link to the icon as otherwise it will render in the wrong color -->
                    <img src="data:image/svg+xml;base64,PHN2ZyB4bWxucz0iaHR0cDovL3d3dy53My5vcmcvMjAwMC9zdmciIGhlaWdodD0iMjQiIHZpZXdCb3g9IjAgMCAyNCAyNCIgd2lkdGg9IjI0Ij48cGF0aCBkPSJNMCAwaDI0djI0SDB6IiBmaWxsPSJub25lIi8+PHBhdGggZmlsbD0iI2ZmZiIgZD0iTTE1LjUgMTRoLS43OWwtLjI4LS4yN0E2LjQ3MSA2LjQ3MSAwIDAgMCAxNiA5LjUgNi41IDYuNSAwIDEgMCA5LjUgMTZjMS42MSAwIDMuMDktLjU5IDQuMjMtMS41N2wuMjcuMjh2Ljc5bDUgNC45OUwyMC40OSAxOWwtNC45OS01em0tNiAwQzcuMDEgMTQgNSAxMS45OSA1IDkuNVM3LjAxIDUgOS41IDUgMTQgNy4wMSAxNCA5LjUgMTEuOTkgMTQgOS41IDE0eiIvPjwvc3ZnPg=="
                         class="usa-search__submit-icon"
                         alt="Search" />
                

        
    
        
            </button>
        


            </form>

            
        

        <!-- Primary navigation menu items -->
        <!-- This usa-nav__inner wrapper is required to correctly style the navigation items on Desktop -->
        

        
            <div class="ncbi-nav__mobile-login-menu ncbi--hide-at-desktop"
                 data-mobile-login-menu
                 hidden>
                <p class="ncbi-nav__mobile-login-menu-status">
                    Logged in as:
                    <strong class="ncbi-nav__mobile-login-menu-email"
                            data-mobile-login-email-text></strong>
                </p>
                <ul class="usa-nav__primary usa-accordion">
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/" class="usa-link  "  >
    

    Dashboard

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/myncbi/collections/bibliography/" class="usa-link  "  >
    

    Publications

    
</a>

                        </li>
                    
                        <li class="usa-nav__primary-item">
                            








<a href="https://www.ncbi.nlm.nih.gov/account/settings/" class="usa-link  "  >
    

    Account settings

    
</a>

                        </li>
                    
                </ul>
            </div>
        

        



















    
        <button
            type="button"
        
    
    class="usa-button
           

           
               
               
               
               
            

           
           
           ncbi-nav__mobile-login-button ncbi--hide-at-desktop
           "
    
    
    
    data-testid="mobileLoginButton"
    data-mobile-login-button
    >
    
        

        Log in

        
    
        
            </button>
        


    </nav>
</header>

    
    
        

<section class="pmc-header pmc-header--basic" aria-label="PMC Header with search box">
    <div class="pmc-nav-container">
        <div class="pmc-header__bar">
           <div class="pmc-header__logo">
               <a href="/" title="Home" aria-label="PMC Home"></a>
           </div>
            <button
                    type="button"
                    class="usa-button usa-button--unstyled pmc-header__search__button"
                    aria-label="Open search"
                    data-ga-category="search"
                    data-ga-action="PMC"
                    data-ga-label="pmc_search_panel_mobile"
            >
                <svg class="usa-icon width-4 height-4 pmc-icon__open" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#search"></use>
                </svg>
                <svg class="usa-icon width-4 height-4 pmc-icon__close" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
            </button>
        </div>
        <div class="pmc-header__search">
            


<form class="usa-search usa-search--extra usa-search--article-right-column  pmc-header__search__form" id="pmc-search-form" autocomplete="off" role="search">
<label class="usa-sr-only" for="pmc-search">Search PMC Full-Text Archive</label>
<span class="autoComplete_wrapper flex-1">
<input class="usa-input width-full maxw-none" required="required" placeholder="Search PMC Full-Text Archive" id="pmc-search"  type="search" name="term" data-autocomplete-url="https://pmc.ncbi.nlm.nih.gov/autocomp/search/autocomp/"/>
</span>
<button
class="usa-button"
type="submit"
formaction="https://www.ncbi.nlm.nih.gov/pmc/"
data-ga-category="search"
data-ga-action="PMC"
data-ga-label="PMC_search_button"
>
<span class="usa-search__submit-text">Search in PMC</span>
<img
src="/static/img/usa-icons-bg/search--white.svg"
class="usa-search__submit-icon"
alt="Search"
/>
</button>
</form>
            <div class="display-flex flex-column tablet:flex-row tablet:flex-justify flex-justify-center flex-align-center width-full desktop:maxw-44">
                <ul class="pmc-header__search__menu">
                    <li>
                        <a class="usa-link" href="https://www.ncbi.nlm.nih.gov/pmc/advanced/" data-ga-action="featured_link" data-ga-label="advanced_search">
                            Advanced Search
                        </a>
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/journals/" data-ga-action="featured_link" data-ga-label="journal list">
                                Journal List
                            </a>
                        
                    </li>
                    <li>
                        
                            <a class="usa-link" href="/about/userguide/" data-ga-action="featured_link"
                            data-ga-label="user guide">
                                User Guide
                            </a>
                        
                    </li>
                </ul>
                
                    <button form="pmc-search-form" formaction="https://pmc.ncbi.nlm.nih.gov/search/" type="submit" class="usa-button usa-button--unstyled hover:text-no-underline text-no-underline width-auto margin-top-1 tablet:margin-top-0">
     <span class="bg-green-label padding-05 text-white">New</span><span class="text-underline text-primary">Try this search in PMC Beta Search</span>
</button>
                
            </div>
        </div>
    </div>
</section>

    


        
        

       
  <div class="usa-section padding-top-0 desktop:padding-top-6 pmc-article-section" data-article-db="pmc" data-article-id="12333935">

    

   



<div class="grid-container pmc-actions-bar" aria-label="Actions bar" role="complementary">
    <div class="grid-row">
        <div class="grid-col-fill display-flex">
             <div class="display-flex">
                <ul class="usa-list usa-list--unstyled usa-list--horizontal">
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <button
                                type="button"
                                class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                                aria-label="Open resources"
                                data-extra-class="is-visible-resources"
                                data-ga-category="resources_accordion"
                                data-ga-action="click"
                                data-ga-label="mobile_icon"
                        >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#more_vert"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex mob">
                        <a
                                href="https://doi.org/10.36469/001c.142078"
                                class="usa-link display-flex usa-tooltip"
                                role="button"
                                target="_blank"
                                rel="noreferrer noopener"
                                title="View on publisher site"
                                data-position="bottom"
                                aria-label="View on publisher site"
                                data-ga-category="actions"
                                data-ga-action="click"
                                data-ga-label="publisher_link_mobile"
                        >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#launch"></use>
                                </svg>
                        </a>
                    </li>
                    
                    
                        <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                             <a
                                     href="pdf/jheor_2025_12_2_142078.pdf"
                                     class="usa-link display-flex usa-tooltip"
                                     role="button"
                                     title="Download PDF"
                                     data-position="bottom"
                                     aria-label="Download PDF"
                                     data-ga-category="actions"
                                     data-ga-action="click"
                                     data-ga-label="pdf_download_mobile"
                             >
                                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                                </svg>
                            </a>
                        </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button
                            class="usa-button usa-button--unstyled  usa-tooltip collections-dialog-trigger collections-button display-flex collections-button-empty"
                            title="Add to Collections"
                            data-position="bottom"
                            aria-label="Save article in MyNCBI collections."
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="collections_button_mobile"
                            data-collections-open-dialog-enabled="false"
                            data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12333935%2F%3Freport%3Dclassic%23open-collections-dialog"
                            data-in-collections="false"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="margin-right-2 mobile-lg:margin-right-4 display-flex">
                        <button role="button" class="usa-button usa-button--unstyled usa-tooltip citation-dialog-trigger display-flex"
                            aria-label="Open dialog with citation text in different styles"
                            title="Cite"
                            data-position="bottom"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="cite_mobile"
                            data-all-citations-url="/resources/citations/12333935/"
                            data-citation-style="nlm"
                            data-download-format-link="/resources/citations/12333935/export/"
                        >
                            <svg class="usa-icon width-4 height-4 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                            </svg>
                        </button>
                    </li>
                    
                    <li class="pmc-permalink display-flex" >
                         <button
                                 type="button"
                                 title="Permalink"
                                 data-position="bottom"
                                 class="usa-button usa-button--unstyled display-flex usa-tooltip"
                                 aria-label="Show article permalink"
                                 aria-expanded="false"
                                 aria-haspopup="true"
                                 data-ga-category="actions"
                                 data-ga-action="open"
                                 data-ga-label="permalink_mobile"
                         >
                            <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                                <use xlink:href="/static/img/sprite.svg#share"></use>
                            </svg>
                        </button>
                        

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333935/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
                    </li>
                </ul>
            </div>
            <button
                    type="button"
                    class="usa-button pmc-sidenav__container__open usa-button--unstyled width-auto display-flex"
                    aria-label="Open article navigation"
                    data-extra-class="is-visible-in-page"
                    data-ga-category="actions"
                    data-ga-action="open"
                    data-ga-label="article_nav_mobile"
            >
                <svg class="usa-icon width-4 height-4" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#list"></use>
                </svg>
            </button>
        </div>
    </div>
</div>
    <div class="grid-container desktop:padding-left-6">
      <div id="article-container" class="grid-row grid-gap">
        <div class="grid-col-12 desktop:grid-col-8 order-2 pmc-layout__content">
            <div class="grid-container padding-left-0 padding-right-0">
                <div class="grid-row desktop:margin-left-neg-6">
                    <div class="grid-col-12">
                        <div class="pmc-layout__disclaimer" role="complementary" aria-label="Disclaimer note">
    As a library, NLM provides access to scientific literature. Inclusion in an NLM database does not imply endorsement of, or agreement with,
    the contents by NLM or the National Institutes of Health.<br/>
    Learn more:
    <a class="usa-link" data-ga-category="Link click" data-ga-action="Disclaimer" data-ga-label="New disclaimer box" href="/about/disclaimer/">PMC Disclaimer</a>
    |
    <a class="usa-link" data-ga-category="Link click" data-ga-action="PMC Copyright Notice" data-ga-label="New disclaimer box" href="/about/copyright/">
        PMC Copyright Notice
    </a>
</div>
                    </div>
                </div>
                <div class="grid-row pmc-wm desktop:margin-left-neg-6">
                    <!-- Main content -->
                    <main
                      id="main-content"
                      class="usa-layout-docs__main usa-layout-docs grid-col-12 pmc-layout pmc-prose padding-0"
                    >

                      
                        <section class="pmc-journal-banner text-center line-height-none" aria-label="Journal banner"><img src="https://cdn.ncbi.nlm.nih.gov/pmc/banners/logo-jheor.png" alt="Journal of Health Economics and Outcomes Research logo" usemap="#pmc-banner-imagemap" width="500" height="75"><map name="pmc-banner-imagemap"><area alt="Link to Journal of Health Economics and Outcomes Research" title="Link to Journal of Health Economics and Outcomes Research" shape="default" href="http://jheor.org/" target="_blank" rel="noopener noreferrer"></map></section><article lang="en"><section aria-label="Article citation and metadata"><section class="pmc-layout__citation font-secondary font-xs"><div>
<div class="display-inline-block"><button type="button" class="cursor-pointer text-no-underline bg-transparent border-0 padding-0 text-left margin-0 text-normal text-primary" aria-controls="journal_context_menu">J Health Econ Outcomes Res</button></div>. 2025 Aug 6;12(2):50–61. doi: <a href="https://doi.org/10.36469/001c.142078" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">10.36469/001c.142078</a>
</div>
<nav id="journal_context_menu" hidden="hidden"><ul class="menu-list font-family-ui" role="menu">
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/pmc/?term=%22J%20Health%20Econ%20Outcomes%20Res%22%5Bjour%5D" class="usa-link" role="menuitem">Search in PMC</a></li>
<li role="presentation"><a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22J%20Health%20Econ%20Outcomes%20Res%22%5Bjour%5D" lang="en" class="usa-link" role="menuitem">Search in PubMed</a></li>
<li role="presentation"><a href="https://www.ncbi.nlm.nih.gov/nlmcatalog?term=%22J%20Health%20Econ%20Outcomes%20Res%22%5BTitle%20Abbreviation%5D" class="usa-link" role="menuitem">View in NLM Catalog</a></li>
<li role="presentation"><a href="?term=%22J%20Health%20Econ%20Outcomes%20Res%22%5Bjour%5D" class="usa-link" role="menuitem" data-add-to-search="true">Add to search</a></li>
</ul></nav></section><section class="front-matter"><div class="ameta p font-secondary font-xs">
<hgroup><h1>Cost per Response of Acthar® Gel vs Standard of Care for the Treatment of Proteinuria in Nephrotic Syndrome Due to Idiopathic Membranous Nephropathy Among Adults from the US Healthcare Perspective</h1></hgroup><div class="cg p">
<a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bindra%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id1"><span class="name western">Jas Bindra</span></a><div hidden="hidden" id="id1">
<h3><span class="name western">Jas Bindra</span></h3>
<div class="p">
<sup>1</sup>Falcon Research Group, North Potomac, Maryland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Bindra%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">Jas Bindra</span></a>
</div>
</div>
<sup>1</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chopra%20I%22%5BAuthor%5D" class="usa-link" aria-describedby="id2"><span class="name western">Ishveen Chopra</span></a><div hidden="hidden" id="id2">
<h3><span class="name western">Ishveen Chopra</span></h3>
<div class="p">
<sup>2</sup>Manticore Consultancy, Bethesda, Maryland</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Chopra%20I%22%5BAuthor%5D" class="usa-link"><span class="name western">Ishveen Chopra</span></a>
</div>
</div>
<sup>2</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hayes%20K%22%5BAuthor%5D" class="usa-link" aria-describedby="id3"><span class="name western">Kyle Hayes</span></a><div hidden="hidden" id="id3">
<h3><span class="name western">Kyle Hayes</span></h3>
<div class="p">
<sup>3</sup>Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Hayes%20K%22%5BAuthor%5D" class="usa-link"><span class="name western">Kyle Hayes</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Niewoehner%20J%22%5BAuthor%5D" class="usa-link" aria-describedby="id4"><span class="name western">John Niewoehner</span></a><div hidden="hidden" id="id4">
<h3><span class="name western">John Niewoehner</span></h3>
<div class="p">
<sup>3</sup>Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Niewoehner%20J%22%5BAuthor%5D" class="usa-link"><span class="name western">John Niewoehner</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Panaccio%20MP%22%5BAuthor%5D" class="usa-link" aria-describedby="id5"><span class="name western">Mary P Panaccio</span></a><div hidden="hidden" id="id5">
<h3><span class="name western">Mary P Panaccio</span></h3>
<div class="p">
<sup>3</sup>Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Panaccio%20MP%22%5BAuthor%5D" class="usa-link"><span class="name western">Mary P Panaccio</span></a>
</div>
</div>
<sup>3</sup>, <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wan%20GJ%22%5BAuthor%5D" class="usa-link" aria-describedby="id6"><span class="name western">George J Wan</span></a><div hidden="hidden" id="id6">
<h3><span class="name western">George J Wan</span></h3>
<div class="p">
<sup>3</sup>Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey</div>
<div class="p">Find articles by <a href="https://pubmed.ncbi.nlm.nih.gov/?term=%22Wan%20GJ%22%5BAuthor%5D" class="usa-link"><span class="name western">George J Wan</span></a>
</div>
</div>
<sup>3,</sup><sup>✉</sup>
</div>
<ul class="d-buttons inline-list">
<li><button class="d-button" aria-controls="aip_a" aria-expanded="false">Author information</button></li>
<li><button class="d-button" aria-controls="anp_a" aria-expanded="false">Article notes</button></li>
<li><button class="d-button" aria-controls="clp_a" aria-expanded="false">Copyright and License information</button></li>
</ul>
<div class="d-panels font-secondary-light">
<div id="aip_a" class="d-panel p" style="display: none">
<div class="p" id="author-aff-1">
<sup>1</sup>Falcon Research Group, North Potomac, Maryland</div>
<div id="author-aff-2">
<sup>2</sup>Manticore Consultancy, Bethesda, Maryland</div>
<div id="author-aff-3">
<sup>3</sup>Mallinckrodt Pharmaceuticals, Bridgewater, New Jersey</div>
<div class="author-notes p"><div class="fn" id="author-note-1">
<sup>✉</sup><p class="display-inline"><strong>Corresponding author:</strong> Email: George.Wan@mnk.com</p>
</div></div>
</div>
<div id="anp_a" class="d-panel p" style="display: none"><div class="notes p"><section id="historyarticle-meta1" class="history"><p>Received 2025 May 27; Accepted 2025 Jul 9; Collection date 2025.</p></section></div></div>
<div id="clp_a" class="d-panel p" style="display: none">
<p>
This is an open access article distributed under the terms of the <a href="https://creativecommons.org/licenses/by/4.0/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Creative Commons Attribution License (4.0)</a>, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
</p>
<div class="p"><a href="/about/copyright/" class="usa-link">PMC Copyright notice</a></div>
</div>
</div>
<div>PMCID: PMC12333935  PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/40787087/" class="usa-link">40787087</a>
</div>
</div></section></section><section aria-label="Article content"><section class="body main-article-body"><section class="abstract" id="abstract1"><h2>Abstract</h2>
<p><strong>Background:</strong> Proteinuria, a critical marker of glomerulosclerosis, poses a challenge in idiopathic membranous nephropathy (iMN), particularly when standard treatments fail. Acthar® Gel, a US Food and Drug Administration–approved treatment option, may offer an alternative for managing refractory proteinuria in nephrotic syndrome (NS) due to iMN where multiple treatments have failed. <strong>Objective:</strong> The cost per response of Acthar® Gel vs standard of care (SoC; cyclophosphamide or rituximab) for treatment of proteinuria in NS due to iMN was evaluated among adults who had failed multiple treatments from a US payer perspective over a 1- to 3-year horizon. <strong>Methods:</strong> A probabilistic, cohort-level state-transition model simulated patient progression through various health states using 6-month cycles. Patients began in a relapse phase and received either Acthar® Gel or SoC. Transition probabilities determined whether patients achieved a response, experienced no response, progressed to renal failure, or remained in relapse. Responders could potentially maintain their response or relapse, while nonresponders risked renal failure, with potential mortality from any state. Clinical, healthcare resource utilization, and cost data were derived from published literature. Drug prices were based on wholesale acquisition costs. <strong>Results:</strong> Over 1 year, Acthar® Gel showed a lower cost per response (<span xmlns:mml="http://www.w3.org/1998/Math/MathML"><math id="mml-equation-62f84291-2c2a-481d-84a7-f0420e7ca17a" display="inline" overflow="linebreak"><mn>377</mn><mrow><mo> </mo></mrow><mn>185</mn><mo stretchy="false">)</mo><mi>t</mi><mi>h</mi><mi>a</mi><mi>n</mi><mi>c</mi><mi>y</mi><mi>c</mi><mi>l</mi><mi>o</mi><mi>p</mi><mi>h</mi><mi>o</mi><mi>s</mi><mi>p</mi><mi>h</mi><mi>a</mi><mi>m</mi><mi>i</mi><mi>d</mi><mi>e</mi><mo stretchy="false">(</mo></math></span>551 687) and rituximab ($741 373). This cost advantage of Acthar® Gel was maintained over 2 and 3 years. Acthar® Gel had higher drug acquisition costs than cyclophosphamide and rituximab but resulted in lower overall medical costs and higher response rates within 1 year, without additional treatment-related costs. Over 2 and 3 years, Acthar® Gel had a lower overall cost of care and higher response rates than SoC, establishing it as a dominant treatment option. <strong>Conclusions:</strong> Based on current model assumptions and clinical inputs, Acthar® Gel may potentially be a cost-effective and value-based treatment strategy vs unapproved SoCs for adults with refractory proteinuria in NS due to iMN, particularly for those who have not responded to conventional therapies over a 1- to 3-year period within a US payer context. These results may inform clinical and payer decision-making in cases when other standard therapies fail to achieve desired outcomes for a specific population.</p>
<section id="kwd-group1" class="kwd-group"><p><strong>Keywords:</strong> Acthar® Gel, cost-per-response, idiopathic membranous nephropathy, nephrotic syndrome, proteinuria, repository corticotropin injection</p></section></section><section id="sec1"><h2 class="pmc_sec_title">INTRODUCTION</h2>
<p>Idiopathic membranous nephropathy (iMN), a leading cause of nephrotic syndrome (NS) in adults, accounts for approximately one-third of biopsy-confirmed diagnoses, as evidenced by a longitudinal study in the US spanning 3 decades.<a href="#ref-476575" class="usa-link" aria-describedby="ref-476575"><sup>1</sup></a> The trajectory of iMN is significantly influenced by the magnitude and duration of this protein excretion.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2</sup></a> Long-term renal outcomes, specifically 10-year kidney survival, are typically observed within a range of 60% to 80%.<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3</sup></a> Moreover, the associated NS can lead to significant health issues, including an increased risk of blood clots, fluid retention, and elevated lipid levels, potentially contributing to substantial patient morbidity and mortality.<a href="#ref-476578" class="usa-link" aria-describedby="ref-476578"><sup>4,5</sup></a></p>
<p>Clinically, iMN often manifests with substantial protein loss in the urine, referred to as proteinuria, a hallmark of NS.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2,3,6</sup></a> Substantial protein loss in the urine is a recognized predictor of progressive kidney dysfunction.<a href="#ref-476581" class="usa-link" aria-describedby="ref-476581"><sup>7</sup></a> Consequently, achieving remission of proteinuria is a central goal of therapeutic intervention.<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3</sup></a> Research has shown that patients experiencing complete or partial remission demonstrate a slower decline in renal function and a reduced risk of end-stage renal disease (ESRD).<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3</sup></a> Notably, complete remission is associated with improved long-term kidney and patient survival.<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3</sup></a> A partial remission also significantly reduces the risk of ESRD progression; even partial remission provides significant protection against ESRD progression.<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3</sup></a></p>
<p>iMN is also characterized by a notable recurrence rate, with up to 30% of patients experiencing relapse.<a href="#ref-476580" class="usa-link" aria-describedby="ref-476580"><sup>6</sup></a> Hence, managing proteinuria in NS due to iMN, particularly in cases refractory to standard treatments, presents a significant clinical challenge.<a href="#ref-476580" class="usa-link" aria-describedby="ref-476580"><sup>6–8</sup></a> The absence of a universally accepted optimal treatment strategy for proteinuria in NS due to iMN among patients who have failed multiple treatments is attributed to the complex and varied underlying disease mechanisms and lack of robust, controlled clinical trials.<a href="#ref-476580" class="usa-link" aria-describedby="ref-476580"><sup>6,8</sup></a> Glucocorticoids remain a standard first-line therapy for glomerular diseases presenting with proteinuria; however, their prolonged use can lead to substantial adverse effects, including bone density loss, steroid-induced diabetes, and weight gain.<a href="#ref-476583" class="usa-link" aria-describedby="ref-476583"><sup>9,10</sup></a> Alternative therapeutic agents, such as calcineurin inhibitors, mycophenolate mofetil, cyclophosphamide, and rituximab, have been explored with varying success.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2,6,8</sup></a> However, these agents often carry significant side effects, such as increased susceptibility to infections and potential relapse upon discontinuation, contributing to disease progression.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2,6,8</sup></a></p>
<p>Approximately one-third of patients with NS due to iMN experience relapse and continue to exhibit persistent or recurrent proteinuria despite standard immunosuppressive therapy, making them the primary candidates for alternative treatments such as Acthar® Gel. Acthar® Gel (repository corticotropin injection, Mallinckrodt Pharmaceuticals) is approved by the US Food and Drug Administration (FDA) to induce a diuresis or a remission of proteinuria in NS without uremia of the idiopathic type or due to lupus erythematosus.<a href="#ref-476585" class="usa-link" aria-describedby="ref-476585"><sup>11</sup></a> It is a naturally sourced complex mixture of adrenocorticotropic hormone analogs and other pituitary peptides that interacts with all 5 melanocortin receptors.<a href="#ref-476585" class="usa-link" aria-describedby="ref-476585"><sup>11</sup></a> This interaction suggests that its therapeutic effects may be mediated through multiple anti-inflammatory pathways, both glucocorticoid-dependent and glucocorticoid-independent.<a href="#ref-476585" class="usa-link" aria-describedby="ref-476585"><sup>11</sup></a> Clinical studies have reported the effectiveness of Acthar® Gel in reducing or inducing remission of proteinuria in NS due to iMN, with safety outcomes characterized.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2,8,12–14</sup></a> With an established side effect profile and a higher likelihood of inducing remission,<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2,8,12–14</sup></a> Acthar® Gel may help appropriate patients with proteinuria in NS due to iMN.</p>
<p>To make informed decisions, clinicians and payers must evaluate clinical outcomes, healthcare resource use, and associated costs of any treatment. This study assessed the cost per response of Acthar® Gel compared with the standard of care (SoC; cyclophosphamide or rituximab) for treatment of proteinuria in NS due to iMN among adults who have not responded to conventional therapies from a US healthcare payer perspective over a 1- to 3-year horizon.</p></section><section id="sec2"><h2 class="pmc_sec_title">METHODS</h2>
<section id="sec3"><h3 class="pmc_sec_title">Model Structure</h3>
<p>A probabilistic, cohort-level state-transition model was developed to assess the economic value of Acthar® Gel in treating proteinuria in NS due to iMN in patients who have not responded to conventional therapies. The model compared the cost per response of Acthar® Gel with that of the SoC, comprising cyclophosphamide and rituximab. Although these SoC agents are recommended in treatment guidelines,<a href="#ref-476580" class="usa-link" aria-describedby="ref-476580"><sup>6</sup></a> their supporting evidence is limited, and they are utilized off-label. Therefore, their safety and efficacy have not been established by the FDA for this indication. The analysis was conducted from a US healthcare payer perspective over a 1- to 3-year period. This study employed Microsoft Excel 2024 to construct and execute the analytical model.</p>
<p>Patient progression through various health states was simulated, integrating uncertainties in the input data (<strong><a href="#attachment-296277" class="usa-link">Figure 1</a></strong>). Initially, all patients entered the model in a relapse phase and received either Acthar® Gel or SoC treatment. The probability of treatment success was applied during the 6-month cycles, consistent with current clinical guidelines and best practices, and patient outcomes were evaluated at the end of each cycle. Following treatment in the relapse phase, patients could move to a response state, move to a persistent NS health state, develop acute renal failure (ARF), or have an unresolved relapse. Patients who discontinued treatment or failed to achieve a clinical response with the assigned therapy were assumed to move to a “persistent NS” health state. Patients who continued to relapse (recurrence of proteinuria after treatment) but demonstrated clinical improvement without meeting formal response criteria, were assumed to receive ongoing treatment. Responders could maintain a sustained response or relapse. Patients in the persistent NS health state were at risk of progressing to renal failure, necessitating dialysis or renal transplantation. Death was possible from any health state.</p>
<figure class="fig xbox font-sm" id="attachment-296277"><h4 class="obj_head">Figure 1. Schematic of the Probabilistic Cohort-Level State-Transition Model for the Treatment of Proteinuria in NS Due to iMN.</h4>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c68/12333935/718e133c28d5/jheor_2025_12_2_142078_296277.jpg" loading="lazy" height="706" width="762" alt="Figure 1."></p>
<div class="p text-right font-secondary"><a href="figure/attachment-296277/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Abbreviations: ARF, acute renal failure; ESRD, end-stage renal disease; iMN, idiopathic membranous nephropathy; NS, nephrotic syndrome; SoC, standard of care.</p>
<p>Persistent NS health state refers to the state to which a patient transitions when a patient fails to show a significant clinical improvement following the full course of the prescribed initial treatment.</p></figcaption></figure></section><section id="sec4"><h3 class="pmc_sec_title">Model Inputs</h3>
<p><strong>Clinical inputs</strong>: Clinical inputs, including effectiveness, safety, complications, pain, depression, disease progression, and mortality, are presented in <strong><a href="#attachment-296280" class="usa-link">Table 1</a></strong>.</p>
<section class="tw xbox font-sm" id="attachment-296280"><h4 class="obj_head">Table 1. Model Inputs: Clinical Inputs and Costs.</h4>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th rowspan="1" colspan="1">
<strong>Parameters<sup>a</sup></strong>
</th>
<th rowspan="1" colspan="1">
<strong>Value ($) or Probability of Event (%)</strong>
</th>
<th rowspan="1" colspan="1">
<strong>Source</strong>
</th>
</tr></thead>
<tbody>
<tr><td colspan="3" rowspan="1">Effectiveness</td></tr>
<tr><td colspan="3" rowspan="1">Acthar® Gel</td></tr>
<tr>
<td rowspan="1" colspan="1">Response</td>
<td rowspan="1" colspan="1">60.0%</td>
<td rowspan="1" colspan="1">Hladunewich et al<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2</sup></a><sup>,d</sup>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">No response<sup>b</sup>
</td>
<td rowspan="1" colspan="1">5.0%</td>
<td rowspan="1" colspan="1">Hladunewich et al<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2</sup></a><sup>,d</sup>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Persistent NS<sup>c</sup>
</td>
<td rowspan="1" colspan="1">35.0%</td>
<td rowspan="1" colspan="1">Hladunewich et al<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2</sup></a><sup>,d</sup>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Relapse</td>
<td rowspan="1" colspan="1">0.1%</td>
<td rowspan="1" colspan="1">Assumption<sup>e</sup>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Cyclophosphamide</td></tr>
<tr>
<td rowspan="1" colspan="1">Response</td>
<td rowspan="1" colspan="1">30.8%</td>
<td rowspan="1" colspan="1">Calculated<sup>f</sup>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">No response<sup>b</sup>
</td>
<td rowspan="1" colspan="1">36.1%</td>
<td rowspan="1" colspan="1">Calculated<sup>f</sup>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Persistent NS<sup>c</sup>
</td>
<td rowspan="1" colspan="1">33.1%</td>
<td rowspan="1" colspan="1">Calculated<sup>f</sup>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Relapse</td>
<td rowspan="1" colspan="1">7.5%</td>
<td rowspan="1" colspan="1">Xue et al<a href="#ref-476590" class="usa-link" aria-describedby="ref-476590"><sup>15</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Rituximab</td></tr>
<tr>
<td rowspan="1" colspan="1">Response</td>
<td rowspan="1" colspan="1">23.0%</td>
<td rowspan="1" colspan="1">Ruggenenti et al<a href="#ref-476589" class="usa-link" aria-describedby="ref-476589"><sup>16</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">No response<sup>b</sup>
</td>
<td rowspan="1" colspan="1">33.2%</td>
<td rowspan="1" colspan="1">Ruggenenti et al<a href="#ref-476589" class="usa-link" aria-describedby="ref-476589"><sup>16</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Persistent NS<sup>c</sup>
</td>
<td rowspan="1" colspan="1">43.8%</td>
<td rowspan="1" colspan="1">Ruggenenti et al<a href="#ref-476589" class="usa-link" aria-describedby="ref-476589"><sup>16</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Relapse</td>
<td rowspan="1" colspan="1">5.0%</td>
<td rowspan="1" colspan="1">Xue et al<a href="#ref-476590" class="usa-link" aria-describedby="ref-476590"><sup>15</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Serious adverse events<sup>g</sup>
</td></tr>
<tr><td colspan="3" rowspan="1">Cyclophosphamide</td></tr>
<tr>
<td rowspan="1" colspan="1">Anemia/leukopenia</td>
<td rowspan="1" colspan="1">30.0%</td>
<td rowspan="1" colspan="1">Fernández-Juárez et al<a href="#ref-476591" class="usa-link" aria-describedby="ref-476591"><sup>17</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Venous thrombosis</td>
<td rowspan="1" colspan="1">12.0%</td>
<td rowspan="1" colspan="1">Fernández-Juárez et al<a href="#ref-476591" class="usa-link" aria-describedby="ref-476591"><sup>17</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Acute kidney injury</td>
<td rowspan="1" colspan="1">19.0%</td>
<td rowspan="1" colspan="1">Fernández-Juárez et al<a href="#ref-476591" class="usa-link" aria-describedby="ref-476591"><sup>17</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Infections</td>
<td rowspan="1" colspan="1">23.0%</td>
<td rowspan="1" colspan="1">Fernández-Juárez et al<a href="#ref-476591" class="usa-link" aria-describedby="ref-476591"><sup>17</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Rituximab</td></tr>
<tr>
<td rowspan="1" colspan="1">Infusion-related adverse events</td>
<td rowspan="1" colspan="1">25.0%</td>
<td rowspan="1" colspan="1">Fervenza et al<a href="#ref-476592" class="usa-link" aria-describedby="ref-476592"><sup>18</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cardiovascular events</td>
<td rowspan="1" colspan="1">1.5%</td>
<td rowspan="1" colspan="1">Fervenza et al<a href="#ref-476592" class="usa-link" aria-describedby="ref-476592"><sup>18</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Increased creatinine levels</td>
<td rowspan="1" colspan="1">6.0%</td>
<td rowspan="1" colspan="1">Fervenza et al<a href="#ref-476592" class="usa-link" aria-describedby="ref-476592"><sup>18</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Endocrine/metabolic events</td>
<td rowspan="1" colspan="1">3.1%</td>
<td rowspan="1" colspan="1">Fervenza et al<a href="#ref-476592" class="usa-link" aria-describedby="ref-476592"><sup>18</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Infections</td>
<td rowspan="1" colspan="1">6.2%</td>
<td rowspan="1" colspan="1">Fervenza et al<a href="#ref-476592" class="usa-link" aria-describedby="ref-476592"><sup>18</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Clinical manifestations</td></tr>
<tr><td colspan="3" rowspan="1">Complications</td></tr>
<tr>
<td rowspan="1" colspan="1">Chronic kidney disease</td>
<td rowspan="1" colspan="1">63.0%</td>
<td rowspan="1" colspan="1">Hayes et al<a href="#ref-476597" class="usa-link" aria-describedby="ref-476597"><sup>19</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cardiac complications</td>
<td rowspan="1" colspan="1">64.1%</td>
<td rowspan="1" colspan="1">Rice et al<a href="#ref-476601" class="usa-link" aria-describedby="ref-476601"><sup>20</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Pain</td></tr>
<tr>
<td rowspan="1" colspan="1">Relapse</td>
<td rowspan="1" colspan="1">58.0%</td>
<td rowspan="1" colspan="1">Lambourg et al<a href="#ref-476595" class="usa-link" aria-describedby="ref-476595"><sup>21</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Persistent NS<sup>c</sup>
</td>
<td rowspan="1" colspan="1">63.0%</td>
<td rowspan="1" colspan="1">Lambourg et al<a href="#ref-476595" class="usa-link" aria-describedby="ref-476595"><sup>21</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hemodialysis</td>
<td rowspan="1" colspan="1">57.1%</td>
<td rowspan="1" colspan="1">Moore et al<a href="#ref-476593" class="usa-link" aria-describedby="ref-476593"><sup>22</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Peritoneal dialysis</td>
<td rowspan="1" colspan="1">58.3%</td>
<td rowspan="1" colspan="1">Moore et al<a href="#ref-476593" class="usa-link" aria-describedby="ref-476593"><sup>22</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Renal transplant</td>
<td rowspan="1" colspan="1">46.0%</td>
<td rowspan="1" colspan="1">Lambourg et al<a href="#ref-476595" class="usa-link" aria-describedby="ref-476595"><sup>21</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Depression</td></tr>
<tr>
<td rowspan="1" colspan="1">Relapse</td>
<td rowspan="1" colspan="1">10.0%</td>
<td rowspan="1" colspan="1">Hayes et al<a href="#ref-476597" class="usa-link" aria-describedby="ref-476597"><sup>19</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Persistent NS<sup>c</sup>
</td>
<td rowspan="1" colspan="1">21.0%</td>
<td rowspan="1" colspan="1">Shirazian et al<a href="#ref-476596" class="usa-link" aria-describedby="ref-476596"><sup>23</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Renal failure</td>
<td rowspan="1" colspan="1">22.8%</td>
<td rowspan="1" colspan="1">Shirazian et al<a href="#ref-476596" class="usa-link" aria-describedby="ref-476596"><sup>23</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Disease progression</td></tr>
<tr>
<td rowspan="1" colspan="1">Relapse to ARF</td>
<td rowspan="1" colspan="1">5.8%</td>
<td rowspan="1" colspan="1">Troyanov et al<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Persistent NS<sup>c</sup> to ARF</td>
<td rowspan="1" colspan="1">10.7%</td>
<td rowspan="1" colspan="1">Troyanov et al<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Persistent NS<sup>c</sup> to ESRD</td>
<td rowspan="1" colspan="1">8.0%</td>
<td rowspan="1" colspan="1">Kolb et al<a href="#ref-476602" class="usa-link" aria-describedby="ref-476602"><sup>24</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ARF to ESRD</td>
<td rowspan="1" colspan="1">4.2%</td>
<td rowspan="1" colspan="1">Coca et al<a href="#ref-476603" class="usa-link" aria-describedby="ref-476603"><sup>25</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Mortality</td></tr>
<tr>
<td rowspan="1" colspan="1">Remission</td>
<td rowspan="1" colspan="1">1.3%</td>
<td rowspan="1" colspan="1">Kolb et al<a href="#ref-476602" class="usa-link" aria-describedby="ref-476602"><sup>24</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Relapse or persistent NS<sup>c</sup>
</td>
<td rowspan="1" colspan="1">2.2%</td>
<td rowspan="1" colspan="1">Kolb et al<a href="#ref-476602" class="usa-link" aria-describedby="ref-476602"><sup>24</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ARF</td>
<td rowspan="1" colspan="1">8.7%</td>
<td rowspan="1" colspan="1">US Renal Data System<a href="#ref-476604" class="usa-link" aria-describedby="ref-476604"><sup>26</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">ESRD</td>
<td rowspan="1" colspan="1">7.2%</td>
<td rowspan="1" colspan="1">US Renal Data System<a href="#ref-476604" class="usa-link" aria-describedby="ref-476604"><sup>26</sup></a>
</td>
</tr>
<tr><td colspan="3" rowspan="1">Direct medical costs (annual)<sup>h,i</sup>
</td></tr>
<tr><td colspan="3" rowspan="1">Supportive care medications</td></tr>
<tr>
<td rowspan="1" colspan="1">ACEi/ARBs</td>
<td rowspan="1" colspan="1">$149</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Beta-blockers</td>
<td rowspan="1" colspan="1">$304</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Calcium channel blockers</td>
<td rowspan="1" colspan="1">$380</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Diuretics</td>
<td rowspan="1" colspan="1">$97</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Anticoagulants</td>
<td rowspan="1" colspan="1">$629</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Statins</td>
<td rowspan="1" colspan="1">$148</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Immunosuppressants</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Systemic corticosteroids</td>
<td rowspan="1" colspan="1">$4383</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cyclosporine</td>
<td rowspan="1" colspan="1">$16 810</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Tacrolimus</td>
<td rowspan="1" colspan="1">$16 843</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Mycophenolate mofetil</td>
<td rowspan="1" colspan="1">$1527</td>
<td rowspan="1" colspan="1">Micromedex Red Book<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Plasmapheresis</td>
<td rowspan="1" colspan="1">$4888</td>
<td rowspan="1" colspan="1">Micromedex Red Book,<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a> Heatwole et al,<a href="#ref-476618" class="usa-link" aria-describedby="ref-476618"><sup>28</sup></a> Winters et al,<a href="#ref-476616" class="usa-link" aria-describedby="ref-476616"><sup>29</sup></a> US BLS<a href="#ref-476617" class="usa-link" aria-describedby="ref-476617"><sup>30</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Pain medications</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Pain medication use</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NSAIDs</td>
<td rowspan="1" colspan="1">$2242</td>
<td rowspan="1" colspan="1">Katz et al<a href="#ref-476619" class="usa-link" aria-describedby="ref-476619"><sup>31</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Opioids</td>
<td rowspan="1" colspan="1">$4071</td>
<td rowspan="1" colspan="1">Ding et al<a href="#ref-476620" class="usa-link" aria-describedby="ref-476620"><sup>32</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Pain medication-related toxicity</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">NSAIDs-related toxicity</td>
<td rowspan="1" colspan="1">$916</td>
<td rowspan="1" colspan="1">Rahme et al<a href="#ref-476626" class="usa-link" aria-describedby="ref-476626"><sup>33</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Opioid-related substance abuse</td>
<td rowspan="1" colspan="1">$50 453</td>
<td rowspan="1" colspan="1">White et al<a href="#ref-476627" class="usa-link" aria-describedby="ref-476627"><sup>34</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Antidepressants use</td>
<td rowspan="1" colspan="1">$3483</td>
<td rowspan="1" colspan="1">Glassman et al<a href="#ref-476628" class="usa-link" aria-describedby="ref-476628"><sup>35</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">iMN-related disease management</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Inpatient</td>
<td rowspan="1" colspan="1">$9340</td>
<td rowspan="1" colspan="1">Nazareth et al<a href="#ref-476611" class="usa-link" aria-describedby="ref-476611"><sup>36</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Outpatient</td>
<td rowspan="1" colspan="1">$17 260</td>
<td rowspan="1" colspan="1">Nazareth et al<a href="#ref-476611" class="usa-link" aria-describedby="ref-476611"><sup>36</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Renal failure management</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Hemodialysis</td>
<td rowspan="1" colspan="1">$188 520</td>
<td rowspan="1" colspan="1">Bhatnagar et al<a href="#ref-476633" class="usa-link" aria-describedby="ref-476633"><sup>37</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Peritoneal dialysis</td>
<td rowspan="1" colspan="1">$174 188</td>
<td rowspan="1" colspan="1">Bhatnagar et al<a href="#ref-476633" class="usa-link" aria-describedby="ref-476633"><sup>37</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Renal transplant</td>
<td rowspan="1" colspan="1">$487 836</td>
<td rowspan="1" colspan="1">Bentley et al<a href="#ref-476634" class="usa-link" aria-describedby="ref-476634"><sup>38</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Complications</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Chronic kidney disease</td>
<td rowspan="1" colspan="1">$17 664</td>
<td rowspan="1" colspan="1">Jha et al<a href="#ref-476629" class="usa-link" aria-describedby="ref-476629"><sup>39</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Major cardiac complications</td>
<td rowspan="1" colspan="1">$21 683</td>
<td rowspan="1" colspan="1">Jha et al<a href="#ref-476629" class="usa-link" aria-describedby="ref-476629"><sup>39</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">End-of-life care</td>
<td rowspan="1" colspan="1">$105 124</td>
<td rowspan="1" colspan="1">French et al<a href="#ref-476630" class="usa-link" aria-describedby="ref-476630"><sup>40</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Serious adverse events (per event)</td>
<td rowspan="1" colspan="1"></td>
<td rowspan="1" colspan="1"></td>
</tr>
<tr>
<td rowspan="1" colspan="1">Anemia/leukopenia</td>
<td rowspan="1" colspan="1">$23 872</td>
<td rowspan="1" colspan="1">Weycker et al<a href="#ref-476640" class="usa-link" aria-describedby="ref-476640"><sup>41</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Venous thrombosis</td>
<td rowspan="1" colspan="1">$19 711</td>
<td rowspan="1" colspan="1">Grosse et al<a href="#ref-476641" class="usa-link" aria-describedby="ref-476641"><sup>42</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Infections</td>
<td rowspan="1" colspan="1">$28 968</td>
<td rowspan="1" colspan="1">Owens et al<a href="#ref-476639" class="usa-link" aria-describedby="ref-476639"><sup>43</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Infusion-related</td>
<td rowspan="1" colspan="1">$9386</td>
<td rowspan="1" colspan="1">Foley et al<a href="#ref-476635" class="usa-link" aria-describedby="ref-476635"><sup>44</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cardiovascular</td>
<td rowspan="1" colspan="1">$29 467</td>
<td rowspan="1" colspan="1">Afana et al<a href="#ref-476637" class="usa-link" aria-describedby="ref-476637"><sup>45</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Endocrine/metabolic or impaired fasting glucose and diabetes mellitus</td>
<td rowspan="1" colspan="1">$15 519</td>
<td rowspan="1" colspan="1">Fingar et al<a href="#ref-476636" class="usa-link" aria-describedby="ref-476636"><sup>46</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Acute kidney injury/increased creatinine level/reversible nephrotoxicity</td>
<td rowspan="1" colspan="1">$49 688</td>
<td rowspan="1" colspan="1">Stottlemyer et al<a href="#ref-476638" class="usa-link" aria-describedby="ref-476638"><sup>47</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Irreversible nephrotoxicity</td>
<td rowspan="1" colspan="1">$180 819</td>
<td rowspan="1" colspan="1">Stottlemyer et al<a href="#ref-476638" class="usa-link" aria-describedby="ref-476638"><sup>47</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Bleeding</td>
<td rowspan="1" colspan="1">$636</td>
<td rowspan="1" colspan="1">Heatwole et al<a href="#ref-476618" class="usa-link" aria-describedby="ref-476618"><sup>28</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Catheter occlusion</td>
<td rowspan="1" colspan="1">$2477</td>
<td rowspan="1" colspan="1">Heatwole et al<a href="#ref-476618" class="usa-link" aria-describedby="ref-476618"><sup>28</sup></a>
</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Corticosteroid-related toxicity (annual)</td>
<td rowspan="1" colspan="1">$87 592</td>
<td rowspan="1" colspan="1">Rice et al<a href="#ref-476642" class="usa-link" aria-describedby="ref-476642"><sup>48</sup></a>
</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/attachment-296280/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p12">
<p>Abbreviations: ACEi, angiotensin-converting enzyme inhibitors; ARBs, angiotensin receptor blockers; ARF, acute renal failure; BLS, Bureau of Labor Statistics; ESRD, end-stage renal disease; iMN, idiopathic membranous nephropathy; NS, nephrotic syndrome; USD, US dollars.</p>
<p><sup>a</sup>All parameters from the literature were converted to a 6-month probability, where applicable.</p>
<p><sup>b</sup>No response refers to patients who initially did not exhibit a therapeutic effect but subsequently achieved a response and experienced resolution of their relapse.</p>
<p><sup>c</sup>Persistent NS health state refers to the state to which a patient transitions when a patient fails to show a significant clinical improvement following the full course of the prescribed initial treatment.</p>
<p><sup>d</sup>Complete remission was defined as proteinuria &lt;0.3 g/day and partial remission as a reduction in proteinuria by &gt;50% with a final urine protein &lt;3.5 g/day, but &gt;0.3 g/day and no response as a reduction in proteinuria by &lt;50% or worsening of proteinuria.</p>
<p><sup>e</sup>A conservative relapse probability of 0.1% was incorporated into the model based on sustained response reported by Bomback et al.<a href="#ref-476586" class="usa-link" aria-describedby="ref-476586"><sup>12</sup></a></p>
<p><sup>f</sup>Cyclophosphamide effectiveness was calculated using a risk ratio from a meta-analysis by Xue et al comparing rituximab and cyclophosphamide.<a href="#ref-476590" class="usa-link" aria-describedby="ref-476590"><sup>15</sup></a></p>
<p><sup>g</sup>No treatment-related serious adverse events were reported for Acthar® Gel in the reviewed studies; therefore, serious adverse events were not considered for Acthar® Gel.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2,8,12–14</sup></a></p>
<p><sup>h</sup>All costs inflated to 2025 USD.</p>
<p><sup>i</sup>Drug costs as of January 1, 2025.</p>
</div></div></section><p>Efficacy data for Acthar® Gel was derived from a phase Ib/II, open-label, dose-finding study, where patients were randomly assigned to receive 40 or 80 units subcutaneously for 3 to 6 months.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2</sup></a> Bomback et al reported sustained responses with Acthar® Gel.<a href="#ref-476586" class="usa-link" aria-describedby="ref-476586"><sup>12</sup></a> Considering the single study reporting a 1-year sustained response without relapse, and the absence of subsequent relapse reports, a conservative relapse probability of 0.1% was incorporated into the model. Rituximab effectiveness data originated from a prospective study of patients referred to a nephrology unit following prior treatment failures.<a href="#ref-476589" class="usa-link" aria-describedby="ref-476589"><sup>16</sup></a> Cyclophosphamide effectiveness was calculated using a risk ratio from a meta-analysis comparing rituximab and cyclophosphamide.<a href="#ref-476590" class="usa-link" aria-describedby="ref-476590"><sup>15</sup></a> Due to the lack of studies examining cyclophosphamide use in patients failing conventional therapies, this approach was utilized, acknowledging the similar efficacy and safety profiles of cyclophosphamide and rituximab. Specifically, we applied the risk ratio reported by Xue et al<a href="#ref-476590" class="usa-link" aria-describedby="ref-476590"><sup>15</sup></a> at 6 months (and at last follow-up) to the observed rituximab response probability via an odds-based transformation, using the following formula:</p>
<figure class="fig xbox font-sm" id="attachment-296281"><p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><img class="graphic" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c68/12333935/baf8ae21da6a/jheor_2025_12_2_142078_296281.jpg" loading="lazy" height="131" width="397" alt="graphic file with name jheor_2025_12_2_142078_296281.jpg"></p>
<div class="p text-right font-secondary"><a href="figure/attachment-296281/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div></figure><p>where p<sub>CYC</sub> = probability of response with cyclophosphamide; p<sub>RTX</sub> = probability of response with rituximab, and RR = risk ratio.</p>
<p>We further assumed that this odds-ratio conversion approximates true relative efficacy sufficiently for modeling purposes and that cyclophosphamide is now less commonly used than rituximab in this patient population. While cyclophosphamide has showed marginally higher efficacy, rituximab exhibits lower toxicity. Relapse probabilities for cyclophosphamide and rituximab were obtained from Xue et al.<a href="#ref-476590" class="usa-link" aria-describedby="ref-476590"><sup>15</sup></a></p>
<p>For cyclophosphamide<a href="#ref-476591" class="usa-link" aria-describedby="ref-476591"><sup>17</sup></a> and rituximab,<a href="#ref-476592" class="usa-link" aria-describedby="ref-476592"><sup>18</sup></a> the analysis only included serious adverse events (SAEs). Studies examining Acthar® Gel reported no treatment-related SAEs; consequently, SAEs were excluded from the Acthar® Gel evaluation.<a href="#ref-476576" class="usa-link" aria-describedby="ref-476576"><sup>2,8,12–14</sup></a></p>
<p>Pain in NS is multifaceted—encompassing nociceptive, neuropathic, and non-neuropathic elements—and is frequently observed in patients with iMN.<a href="#ref-476593" class="usa-link" aria-describedby="ref-476593"><sup>22</sup></a> In patients with ESRD, pain is widespread and contributes significantly to depression, disrupted sleep, reduced dialysis efficacy, and an increased tendency to withdraw from dialysis.<a href="#ref-476594" class="usa-link" aria-describedby="ref-476594"><sup>49</sup></a> Thus, the model incorporated pain prevalence using estimates from the literature.<a href="#ref-476593" class="usa-link" aria-describedby="ref-476593"><sup>21,22</sup></a> Similarly, depression is common in chronic kidney disease, including ESRD, and is linked to diminished quality of life and higher mortality<a href="#ref-476596" class="usa-link" aria-describedby="ref-476596"><sup>23</sup></a>; accordingly, depression prevalence was also integrated into the model based on published data.<a href="#ref-476596" class="usa-link" aria-describedby="ref-476596"><sup>19,23</sup></a></p>
<p>Persistent proteinuria in NS due to iMN increases the risk of chronic complications, including hypertension, hyperlipidemia, and venous thrombosis.<a href="#ref-476598" class="usa-link" aria-describedby="ref-476598"><sup>50–52</sup></a> These conditions contribute to cardiac complications and accelerate the progression of chronic kidney disease.<a href="#ref-476598" class="usa-link" aria-describedby="ref-476598"><sup>50–52</sup></a> The probabilities of these complications were derived from published studies.<a href="#ref-476597" class="usa-link" aria-describedby="ref-476597"><sup>19,20</sup></a></p>
<p>In patients with iMN, kidney failure progression is primarily observed in relapsing and persistent NS health states. Given the limited data on Acthar® Gel and SoC, equivalent progression probabilities for both treatment groups were assumed.<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3,24,25</sup></a> NS is also linked to a greater risk of mortality from complications, such as infections, kidney failure, and thrombosis, with 6-month excess mortality probabilities derived from the literature.<a href="#ref-476602" class="usa-link" aria-describedby="ref-476602"><sup>24,26</sup></a></p>
<p><strong>Cost inputs</strong>: Wholesale acquisition costs (as of January 1, 2025), were sourced from the Micromedex Red Book (Merative).<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27</sup></a> The cost of a 5 mL multidose vial of Acthar® Gel was $45 304; an average utilization of 7.86 vials per year (based on the specialty pharmacy dispensing data for 12 months ending December 31, 2023) was considered in the model. The total cost for SoC was calculated based on dosing information from the literature and clinical guidelines.<a href="#ref-476580" class="usa-link" aria-describedby="ref-476580"><sup>6,53</sup></a> Dosage was calculated considering an average body weight of 80.0 kg and a body surface area of 2.0 m². The annual cost of cyclophosphamide was $8554. Additionally, the rituximab cost calculation factored in the prices and market shares of the original biologic and its biosimilars, resulting in an annual cost of $103 242.</p>
<p>Administration costs of $4170 per year were applied exclusively to rituximab, given its intravenous delivery mode of administration.<a href="#ref-476607" class="usa-link" aria-describedby="ref-476607"><sup>54</sup></a> Both cyclophosphamide and rituximab require monitoring, with annual costs estimated at $480.<a href="#ref-476607" class="usa-link" aria-describedby="ref-476607"><sup>54</sup></a> Further, immunosuppressants require antibiotic prophylaxis, and trimethoprim/sulfamethoxazole use was considered, with an annual cost of $250.<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27,55</sup></a> Additionally, anti-emetic costs were factored into the overall administration costs at an annual cost of $877.<a href="#ref-476609" class="usa-link" aria-describedby="ref-476609"><sup>56</sup></a></p>
<p>The model encompassed a variety of costs associated with the management of proteinuria in NS due to iMN across different health states. These costs included those for supplementary treatments (supportive care medications, immunosuppressants, plasmapheresis, and medications for pain medications, and antidepressants), iMN-related disease management (both inpatient and outpatient), complications, end-of-life care, and kidney failure management (dialysis or renal transplant) (<strong><a href="#attachment-296280" class="usa-link">Table 1</a></strong>). All cost estimates were derived from published literature and adjusted to 2025 US dollars using the US Consumer Price Index for Medical Care Services for Urban Consumers.<a href="#ref-476610" class="usa-link" aria-describedby="ref-476610"><sup>57</sup></a></p>
<p>Patients in every health state, except for those who had died, were assumed to receive supportive care medications to manage NS-related comorbidities such as deep vein thrombosis, hypertension, hyperlipidemia, and stroke. Utilization rates for these medications were as follows: angiotensin-converting enzyme inhibitors (ACEis) or angiotensin receptor blockers (ARBs) at 69.4%, beta-blockers at 22.2%, calcium channel blockers at 13.9%, diuretics at 73.6%, anticoagulants at 16.7%, and statins at 68.1%; derived from the Symphony Health database (January 1, 2016–December 31, 2022).</p>
<p>Patients in persistent NS health state were assumed to be treated with immunosuppressive therapies to control proteinuria. The treatment mix was distributed as follows: chronic systemic corticosteroids use at 25.0%,<a href="#ref-476597" class="usa-link" aria-describedby="ref-476597"><sup>19</sup></a> cyclosporine at 11.0%,<a href="#ref-476611" class="usa-link" aria-describedby="ref-476611"><sup>36</sup></a> tacrolimus at 11.1%<a href="#ref-476611" class="usa-link" aria-describedby="ref-476611"><sup>36</sup></a> and mycophenolate mofetil at 12.3%.<a href="#ref-476611" class="usa-link" aria-describedby="ref-476611"><sup>36</sup></a> Chronic corticosteroid use was presumed, meaning that all patients were at risk of experiencing corticosteroid-associated toxicity. Based on the published literature, SAEs for cyclosporine were distributed as 10.8% for cardiovascular events, 12.3% for infections, 3.1% for nephrotoxicity, and 1.5% for endocrine/metabolic issues.<a href="#ref-476592" class="usa-link" aria-describedby="ref-476592"><sup>18</sup></a> For tacrolimus, SAEs included 15.9% for reversible nephrotoxicity, 9.0% for irreversible nephrotoxicity, 43.1% for infections, and 22.7% for impaired fasting glucose/diabetes mellitus.<a href="#ref-476612" class="usa-link" aria-describedby="ref-476612"><sup>58</sup></a> Additionally, 3.0% of patients were assumed to undergo plasmapheresis.<a href="#ref-476613" class="usa-link" aria-describedby="ref-476613"><sup>59</sup></a> Data on the number of sessions<a href="#ref-476614" class="usa-link" aria-describedby="ref-476614"><sup>60</sup></a> and related expenses—covering acquisition, staffing, equipment, materials, and laboratory tests—were used to calculate the cost per session.<a href="#ref-476605" class="usa-link" aria-describedby="ref-476605"><sup>27–30,61</sup></a> The SAE profile for plasmapheresis was 4.9% for bleeding, 2.4% for catheter occlusion, 2.4% for deep vein thrombosis, and 2.4% for infections.<a href="#ref-476618" class="usa-link" aria-describedby="ref-476618"><sup>28</sup></a></p>
<p>Pain management strategies incorporated the use of nonsteroidal anti-inflammatory drugs (NSAIDs) and opioids.<a href="#ref-476619" class="usa-link" aria-describedby="ref-476619"><sup>31,32</sup></a> NSAID use was restricted to patients in the relapse phase because of concerns regarding worsening kidney function in persistent NS and renal failure health states.<a href="#ref-476621" class="usa-link" aria-describedby="ref-476621"><sup>62</sup></a> Utilization rates and toxicity risks for both NSAIDs and opioids were derived from the literature. In the relapse phase, 43.1% of patients used NSAIDs, while 52.8% used opioids [Symphony Health database (January 1, 2016–December 31, 2022)]. Opioids were estimated to be used by 20% of patients in the persistent NS health state,<a href="#ref-476622" class="usa-link" aria-describedby="ref-476622"><sup>63</sup></a> 40.6% of those on hemodialysis or peritoneal dialysis,<a href="#ref-476623" class="usa-link" aria-describedby="ref-476623"><sup>64</sup></a> and 60.0% of those with a kidney transplant.<a href="#ref-476624" class="usa-link" aria-describedby="ref-476624"><sup>65</sup></a> The likelihood of NSAID-related toxicity was 25%,<a href="#ref-476625" class="usa-link" aria-describedby="ref-476625"><sup>66</sup></a> and chronic opioid use was presumed to elevate the risk of opioid abuse. Costs associated with managing pain-medication toxicity were also obtained from published sources.<a href="#ref-476626" class="usa-link" aria-describedby="ref-476626"><sup>33,34</sup></a> Furthermore, costs for antidepressants were considered for patients who did not achieve a treatment response.<a href="#ref-476628" class="usa-link" aria-describedby="ref-476628"><sup>35</sup></a></p>
<p>Management costs of iMN encompassed inpatient and outpatient services for patients in persistent NS health state.<a href="#ref-476611" class="usa-link" aria-describedby="ref-476611"><sup>36</sup></a> Costs related to complications were assigned to patients with complications in persistent NS health state and disease progression,<a href="#ref-476629" class="usa-link" aria-describedby="ref-476629"><sup>39</sup></a> and end-of-life care costs for deceased patients were also considered.<a href="#ref-476630" class="usa-link" aria-describedby="ref-476630"><sup>40</sup></a> Management of ARF involved dialysis, with 89% of patients on hemodialysis and 11% on peritoneal dialysis.<a href="#ref-476631" class="usa-link" aria-describedby="ref-476631"><sup>67,68</sup></a> For ESRD, treatment options included dialysis (70%) or renal transplant (30%).<a href="#ref-476632" class="usa-link" aria-describedby="ref-476632"><sup>68</sup></a> Dialysis-related costs were applied to ARF patients, while ESRD patients incurred dialysis and/or transplantation costs.<a href="#ref-476633" class="usa-link" aria-describedby="ref-476633"><sup>37,38</sup></a> Additionally, costs associated with SAEs varied by treatment and were calculated based on the frequency and type of SAEs observed for each therapy, with SAE costs for SoC reported separately.<a href="#ref-476618" class="usa-link" aria-describedby="ref-476618"><sup>28,41–48</sup></a></p></section><section id="sec5"><h3 class="pmc_sec_title">Cost-per-Response Analysis</h3>
<p>The core analysis (base case) assessed one-year cost per response for Acthar® Gel and SoC treatments. This was computed by dividing the total healthcare costs per patient by the proportion of patients achieving resolved relapse within each treatment group. The cost per response was also evaluated at 2 and 3 years, as part of extended analyses. Additionally, the incremental cost-effectiveness was examined by calculating the difference in total healthcare costs per patient between the two treatment groups (incremental cost) divided by the difference in the proportion of patients achieving response between the two treatment groups (incremental response) across the specified time horizons.</p>
<p>Several key assumptions were made to reflect a population with refractory and persistent proteinuria in NS due to iMN and utilizing the best available data specific to this population. Acthar® Gel was modeled only in patients who have failed at least 2 prior therapies (including corticosteroids), consistent with its real-world clinical practice. In the absence of long-term relapse data for Acthar® Gel, an annual relapse rate of 0.1% was conservatively applied. Similarly, comparator therapies (off-label cyclophosphamide and rituximab) have been evaluated primarily in refractory cohorts with limited randomized evidence, only SAEs requiring hospitalizations were captured, consistent with FDA definitions and standard cost-effectiveness methodology and excluded less severe events. Further, SAEs were defined a priori as those necessitating hospitalization and therefore included only hospitalization-level events (eg, neutropenia, anemia) for cyclophosphamide and rituximab. Adverse events reported in Acthar® Gel studies (weight gain, hypertension, edema, fatigue, seizures) did not meet this hospitalization threshold, nor were they adjudicated as treatment-related, and thus were excluded. Deterministic and probabilistic sensitivity analyses were used to evaluate the baseline assumptions and influence of variations in model parameters to assess the robustness of the 1-year cost-per-response findings for Acthar® Gel vs SoC. A one-way deterministic sensitivity analysis was performed by altering each key model input by ±30% and drug acquisition costs by ±10%. A multivariable probabilistic sensitivity analysis was conducted using 5000 Monte Carlo simulations, where parameter values were randomly sampled from predefined probability distributions, allowing for a comprehensive evaluation of combined uncertainty. The selection of these distributions was informed by the inherent characteristics and limitations of the available data, ensuring that the full range of potential uncertainty was adequately captured.</p></section></section><section id="sec6"><h2 class="pmc_sec_title">RESULTS</h2>
<p>Over 1 year, Acthar® Gel exhibited a lower cost per response ($377 185) than cyclophosphamide ($551 687) and rituximab ($741 373) (<strong><a href="#attachment-296282" class="usa-link">Figure 2</a></strong>). Relative to cyclophosphamide, Acthar® Gel incurred an additional $17 796 per patient yet delivered a 22.9% higher response rate. Compared with rituximab, Acthar® Gel cost an additional $18 128 per patient while achieving a 33.0% higher response rate (<strong><a href="#attachment-296283" class="usa-link">Figure 3</a></strong>). Although Acthar® Gel’s drug acquisition cost was $170 666 higher than cyclophosphamide and $93 749 higher than rituximab, it resulted in lower overall medical costs resulting from other treatments, disease management, and renal failure and did not incur any treatment-related expenses (administration/monitoring and adverse events) over 1 year.</p>
<figure class="fig xbox font-sm" id="attachment-296282"><h3 class="obj_head">Figure 2. Cost per Response Over 1 Year From a US Payer Perspective.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333935_jheor_2025_12_2_142078_296282.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c68/12333935/480e29dfae19/jheor_2025_12_2_142078_296282.jpg" loading="lazy" height="504" width="730" alt="Figure 2."></a></p>
<div class="p text-right font-secondary"><a href="figure/attachment-296282/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Abbreviation: USD, US dollar.</p>
<p>Note: Results are presented on a per-person basis. Size of the bubble in the plot represents cost-per-response.</p></figcaption></figure><figure class="fig xbox font-sm" id="attachment-296283"><h3 class="obj_head">Figure 3. Overall Cost of Care and Response Rate Over 1 Year From a US Payer Perspective.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333935_jheor_2025_12_2_142078_296283.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c68/12333935/85e92674b4bc/jheor_2025_12_2_142078_296283.jpg" loading="lazy" height="329" width="718" alt="Figure 3."></a></p>
<div class="p text-right font-secondary"><a href="figure/attachment-296283/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Abbreviation: iMN, idiopathic membranous nephropathy. Numbers in bold represent total costs.</p>
<p>Results are presented on a per-person basis; All costs inflated to 2025 US dollars.</p></figcaption></figure><p>Other treatments include immunosuppressants (including monitoring and serious adverse events costs), supportive care treatments (antihypertensives, anticoagulants, and statins), plasmapheresis, pain medications, antidepressants; Disease management includes iMN-related inpatient and outpatient (physician office visits, emergency department, other outpatient); Renal failure management includes disease progression costs, including dialysis, renal transplant, and complications.</p>
<p>The cost-per-response benefit with Acthar® Gel over cyclophosphamide and rituximab was maintained at an extended time horizon of 2 and 3 years (<strong><a href="#attachment-296284" class="usa-link">Table 2</a></strong>). Specifically, Acthar® Gel had lower overall care costs and higher response rates relative to cyclophosphamide and rituximab at these extended time points. The patterns of overall care costs at extended time horizons mirrored those seen at 1 year (<strong>Supplementary Table S1</strong>).</p>
<section class="tw xbox font-sm" id="attachment-296284"><h3 class="obj_head">Table 2. Cost per Response at 2 and 3 Years from a US Payer Perspective.</h3>
<div class="tbl-box p" tabindex="0"><table class="content" frame="hsides" rules="groups">
<thead><tr>
<th rowspan="1" colspan="1">
<strong>Timeframe and Intervention</strong>
</th>
<th rowspan="1" colspan="1">
<strong>Costs per Patient,<sup>a</sup> $</strong>
</th>
<th rowspan="1" colspan="1">
<strong>Response Rate, %</strong>
</th>
<th rowspan="1" colspan="1">
<strong>Cost per Response,<sup>b</sup> $</strong>
</th>
</tr></thead>
<tbody>
<tr><td colspan="4" rowspan="1">2 years</td></tr>
<tr>
<td rowspan="1" colspan="1">Acthar® Gel</td>
<td rowspan="1" colspan="1">298 671</td>
<td rowspan="1" colspan="1">60.7</td>
<td rowspan="1" colspan="1">492 044</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cyclophosphamide</td>
<td rowspan="1" colspan="1">378 855</td>
<td rowspan="1" colspan="1">39.6</td>
<td rowspan="1" colspan="1">956 705</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Rituximab</td>
<td rowspan="1" colspan="1">381 399</td>
<td rowspan="1" colspan="1">29.6</td>
<td rowspan="1" colspan="1">1 288 510</td>
</tr>
<tr><td colspan="4" rowspan="1">3 years</td></tr>
<tr>
<td rowspan="1" colspan="1">Acthar® Gel</td>
<td rowspan="1" colspan="1">366 775</td>
<td rowspan="1" colspan="1">59.2</td>
<td rowspan="1" colspan="1">619 552</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Cyclophosphamide</td>
<td rowspan="1" colspan="1">540 223</td>
<td rowspan="1" colspan="1">36.3</td>
<td rowspan="1" colspan="1">1 488 218</td>
</tr>
<tr>
<td rowspan="1" colspan="1">Rituximab</td>
<td rowspan="1" colspan="1">550 043</td>
<td rowspan="1" colspan="1">27.3</td>
<td rowspan="1" colspan="1">2 014 810</td>
</tr>
</tbody>
</table></div>
<div class="p text-right font-secondary"><a href="table/attachment-296284/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<div class="tw-foot p"><div class="fn" id="_fn_p45">
<p><sup>a</sup>All costs inflated to 2025 US dollars.</p>
<p><sup>b</sup>Results are presented on a per-person basis.</p>
</div></div></section><p>Acthar® Gel was a dominant treatment strategy in this economic evaluation vs unapproved treatments, cyclophosphamide and rituximab at 2 and 3 years, with lower costs and higher response rates (<strong>Supplementary Table S2</strong>).</p>
<p>The deterministic sensitivity analysis identified key contributors to cost per response over 1 year (<strong><a href="#attachment-296285" class="usa-link">Figure 4</a></strong>). The key contributors to cost per response for Acthar® Gel vs cyclophosphamide were the response rate and rate of persistent NS with Acthar® Gel, immunosuppressants-related toxicity, acquisition cost of Acthar® Gel, and cyclophosphamide-related SAEs. The key contributors to cost per response for Acthar® Gel vs rituximab were the response rate and rate of persistent NS with Acthar® Gel, the acquisition cost of Acthar® Gel and rituximab, and rituximab-related SAEs.</p>
<figure class="fig xbox font-sm" id="attachment-296285"><h3 class="obj_head">Figure 4. Key Drivers of Cost per Response Based on Deterministic Sensitivity Analysis of Acthar® Gel vs (<strong>A</strong>) Cyclophosphamide and (<strong>B</strong>) Rituximab Over 1 Year From a US Payer Perspective.</h3>
<p class="img-box line-height-none margin-x-neg-2 tablet:margin-x-0 text-center"><a class="tileshop" target="_blank" href="https://www.ncbi.nlm.nih.gov/core/lw/2.0/html/tileshop_pmc/tileshop_pmc_inline.html?title=Click%20on%20image%20to%20zoom&amp;p=PMC3&amp;id=12333935_jheor_2025_12_2_142078_296285.jpg"><img class="graphic zoom-in" src="https://cdn.ncbi.nlm.nih.gov/pmc/blobs/4c68/12333935/2c126dc53877/jheor_2025_12_2_142078_296285.jpg" loading="lazy" height="321" width="678" alt="Figure 4."></a></p>
<div class="p text-right font-secondary"><a href="figure/attachment-296285/" class="usa-link" target="_blank" rel="noopener noreferrer">Open in a new tab</a></div>
<figcaption><p>Abbreviations: NS, nephrotic syndrome; USD, US dollars.</p>
<p>Notes:</p>
<p>1. Persistent NS health state refers to the state to which a patient transitions when a patient fails to show a significant clinical improvement following the full course of the prescribed initial treatment.</p>
<p>2. Bars represent the variation in the cost-per-response corresponding to high and low variation on a parameter’s point estimate. The “lower bound” represents the model outcome when a specific parameter is set to its minimum value within the specified range, while holding all other parameters at their base or central values. The “upper bound” represents the model outcome when a specific parameter is set to its maximum value within the specified range, while holding all other parameters at their base or central values. The vertical line dividing the lower and upper bound bars represents the base case cost-per-response when all inputs are set to their base case estimates.</p>
<p>3. Parameters are presented in a ranked order, with the most influential variables at the top. The length of the bars represents the magnitude of impact, and their direction (left or right) indicates whether the impact is positive or negative. If the impact of an input is positively related, then increasing the input estimate increases the cost-per-response (upper bound bar extends to the right; lower bound bar to the left) and vice versa. Conversely, if the impact of an input is negatively related, then increasing the input estimate decreases the cost-per-response (upper bound bar extends to the left; lower bound bar to the right) and vice versa.</p></figcaption></figure><p>The probabilistic sensitivity analysis showed that Acthar® Gel was cost-effective in 77.4% of iterations vs cyclophosphamide and 91.3% of iterations vs rituximab at a willingness-to-pay threshold of $150 000 per response over 1 year (<strong>Supplementary Figure S1</strong>).</p></section><section id="sec7"><h2 class="pmc_sec_title">DISCUSSION</h2>
<p>Proteinuria plays a pivotal role in the progression of NS due to iMN and is a well-established risk factor for advancing renal disease.<a href="#ref-476577" class="usa-link" aria-describedby="ref-476577"><sup>3,7</sup></a> Addressing proteinuria in NS, particularly in cases refractory to conventional treatments, poses significant challenges due to the absence of uniformly accepted therapeutic approaches.<a href="#ref-476580" class="usa-link" aria-describedby="ref-476580"><sup>6–8</sup></a> This analysis assessed the economic value of treatment strategies for adults with proteinuria in NS due to iMN.</p>
<p>Over a period of 1 to 3 years, the findings indicated a more favorable cost per response for Acthar® Gel when compared with off-label therapies such as cyclophosphamide and rituximab. This economic advantage was consistently shown across a range of sensitivity analyses, reinforcing the robustness of the result. Notably, the analysis also showed that Acthar® Gel resulted in lower overall medical costs throughout the evaluation period. Consequently, Acthar® Gel presented as a dominant strategy, achieving both cost savings and improved response rates throughout the extended 2 and 3-year analysis timeframe.</p>
<p>Deterministic sensitivity analysis revealed that the higher response rate associated with Acthar® Gel was the primary factor driving its lower cost per response compared with SoC. Several other important cost drivers contributed to the more advantageous economic profile of Acthar® Gel relative to both SoCs. Other key drivers were a lower or similar probability of patients treated with Acthar® Gel progressing to the persistent NS health state, a higher likelihood of SAEs with SoC, and the higher initial acquisition cost of Acthar® Gel. Further analysis identified specific factors that were key drivers in the individual comparisons between Acthar® Gel and the off-label therapies. In the comparison with cyclophosphamide, a higher probability of immunosuppressant-related toxicity associated with cyclophosphamide was a significant factor. Similarly, the higher acquisition cost of rituximab was a key driver in its respective comparison with Acthar® Gel.</p>
<p>While the initial acquisition cost of Acthar® Gel was higher, the elimination of treatment-related costs associated with administration, monitoring, and the management of adverse events led to reduced overall healthcare spending. Further, the improved response rate translated to a decreased need for supportive and subsequent treatments, including immunosuppressive agents, plasmapheresis, and medications for pain and depression, disease management services, and costly interventions like dialysis and renal transplantation, effectively balancing the higher drug cost.</p>
<p>This study represents the first economic evaluation comparing the clinical outcomes and cost implications of treatment options for refractory proteinuria in NS due to iMN among patients who have failed on conventional therapies from a US payer perspective. It offers novel insights into a chronic, persistent, and refractory condition where evidence is currently limited. By mapping potential health states and transitions, the model provides a comprehensive framework for assessing alternative treatments’ short-term clinical and economic impacts on proteinuria in NS due to iMN. The transitions among health states in the model carry significant implications for both clinicians and payers. For example, the possibility of moving from a relapse to a response state highlights the differences in treatment effectiveness and underscores the need for personalized approaches. Similarly, the potential for cycling between relapse and response states emphasizes the chronic nature of proteinuria in NS due to iMN and the likelihood of ongoing treatment requirements. Transitions to acute or chronic renal failure further illustrate the potential severity of the disease and the consequent need for intensive interventions such as dialysis or transplantation, factors that incur substantial costs for payers. Moreover, the study’s findings provide clinicians and payers with important data that can be used to inform treatment decisions for adults who do not respond to conventional treatments. Given that proteinuria in NS due to iMN is challenging to manage, treatment selection involves an integrated approach, including the patient’s clinical profile, physician’s judgment, and the availability of resources. Finally, this analysis establishes a foundation for future research, including investigations into long-term clinical and economic outcomes and the identification of patient subgroups who may derive greater benefit from Acthar® Gel.</p>
<p>Optimal management of proteinuria in NS due to iMN aims to induce remission, mitigate complications, and delay renal failure, thereby lessening the economic impact. Consequently, it is crucial to evaluate therapies based on their capacity to deliver favorable clinical outcomes in a cost-effective manner.<a href="#ref-476643" class="usa-link" aria-describedby="ref-476643"><sup>69</sup></a> This analysis highlights the significant influence of Acthar® Gel’s greater response rate on its cost-per-response profile for the treatment of proteinuria in NS due to iMN. Despite a higher initial acquisition cost, the observed decrease in downstream healthcare costs underscores the potential for therapies with improved response rates to achieve treatment targets and generate cost efficiencies. This reinforces that interventions with better response rates can meet treatment objectives and provide cost savings for healthcare systems. The favorable cost per response of Acthar® Gel vs off-label SoC treatments could be further optimized through strategic pricing strategies (eg, rebates, discounts), further strengthening its value proposition as a potentially economically viable treatment option.</p>
<p>Immunosuppressant-related toxicity emerged as one of the major cost determinants in the comparison of Acthar® Gel and cyclophosphamide. Cyclophosphamide regimens, often also including systemic corticosteroids, carry a risk of long-term toxicity.<a href="#ref-476583" class="usa-link" aria-describedby="ref-476583"><sup>9,10</sup></a> SAEs associated with these SoC treatments also had a substantial impact on the economic analysis. Acthar® Gel showed an advantageous cost per response vs these off-label SoCs, signifying possible reductions in healthcare costs and improved clinical benefits through lower treatment-related toxicity rates.</p>
<p>This economic analysis acknowledges several inherent limitations. First, this analysis, conducted from a US payer perspective, may not be fully applicable to healthcare systems with alternative treatment protocols for adults with proteinuria in NS due to iMN. Second, the reliance on published observational studies for clinical and cost data may have introduced the possibility of deviations from real-world practice. Third, precisely quantifying the complex influence of proteinuria in NS due to iMN on health outcomes and resource consumption remains difficult due to limited data availability. Fourth, the model did not incorporate potential pricing adjustments from the manufacturer, such as discounts or rebates. Fifth, the absence of direct, randomized controlled trials and the off-label use of SoC treatments, supported by limited studies in refractory proteinuria in NS due to iMN, necessitated the use of indirect data, introducing a degree of uncertainty. Clinical efficacy inputs for Acthar® Gel are based on small Phase Ib/II trials and observational cohorts, rather than head-to-head randomized comparisons with off-label therapies, which may limit the precision of transition probability estimates. Although sensitivity analyses suggest that the assumed 0.1% relapse rate has minimal impact on cost results, it remains an area of uncertainty. A targeted, comprehensive literature search was conducted to capture data relevant to the specific population considered in this model; however, unpublished data or ongoing trials could alter the evidence base, and potential publication bias should be considered when interpreting study findings. Sixth, less severe AEs reported in some Acthar® Gel studies were not considered in this analysis as they did not meet the <em>a priori</em> definition of SAEs. While the selective inclusion of AEs could potentially lead to an underestimation of total costs, particularly for Acthar® Gel, it is essential to note that the exclusion of non-severe AEs also applies to the off-label comparator therapies. Furthermore, sensitivity analyses demonstrated that the inclusion of SAEs had a minimal impact on the overall cost-per-response outcomes, suggesting that this limitation likely has a limited effect on the study’s primary findings. Finally, this study was conducted from a US healthcare payer perspective, where decision-makers often focus on direct clinical outcomes. Furthermore, this analysis focused on short-term outcomes, primarily encompassing clinical benefits for a very specific population. Therefore, cost per response was a primary metric as response rates are the endpoints most directly measured and acted upon by payers in this setting. Further studies are needed to include cost per quality-adjusted life-years as an outcome, once long-term data and health utility data become available, allowing for direct comparability with other treatment economic evaluations.</p>
<p>Given the preliminary nature and reliance on modeled assumptions, the results are best viewed as hypothesis-generating. Further clinical studies would be valuable to help validate key inputs such as efficacy and relapse rates. Given the acknowledged limitations related to the limited randomized controlled trial data, relapse rates, heterogeneity in source populations, and SAE classification, the study conclusions rely on these assumptions and may change with the emergence of more robust clinical evidence. To address these limitations, the robustness of the results was evaluated through sensitivity analyses, which consistently validated Acthar® Gel’s advantageous cost-per-response profile. Head-to-head trials or registry data are needed to confirm the durability of response and capture the full safety profile.</p>
<p>The findings from this economic analysis should be interpreted in the context of the available data and underlying model assumptions and are intended to be viewed as preliminary and hypothesis-generating given the current evidence base in this population. Notwithstanding these limitations, the study suggests Acthar® Gel may represent a potentially value-based treatment strategy for adults with proteinuria in NS due to iMN. The observed favorable cost per response is primarily attributed to its enhanced response rate, which in turn minimizes the requirement for subsequent, high-cost interventions. This reduction in healthcare resource utilization effectively mitigates the initial drug expenditure, resulting in overall cost efficiencies. This analysis emphasizes the importance of a value-focused approach to treatment decisions for therapies that enhance patient outcomes and optimize healthcare resource allocation.</p></section><section id="sec8"><h2 class="pmc_sec_title">CONCLUSIONS</h2>
<p>This analysis indicates that, based on the current assumptions and clinical inputs, Acthar® Gel has the potential to be a cost-effective and value-based treatment strategy compared with unapproved SoCs for adults with refractory proteinuria in NS due to iMN, particularly for those who have failed multiple treatments. While the conclusions of this economic analysis are based on the available model inputs, they provide valuable preliminary insights and help generate hypotheses for further research, particularly given the limited data in this population. These results may inform clinical and payer decision-making in cases where standard therapies fail to achieve desired outcomes for a specific population. Additional research is needed to assess the long-term benefits of Acthar® Gel. Future research, including head-to-head trials or registry studies, is needed to confirm the durability of response and to fully characterize the safety profile.</p></section><section id="sec9"><h2 class="pmc_sec_title">Supplementary Material</h2>
<section class="sm xbox font-sm" id="attachment-297142"><div class="caption p"><span>Online Supplementary Material</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12333935/bin/jheor_2025_12_2_142078_297142.pdf" data-ga-action="click_feat_suppl" class="usa-link">jheor_2025_12_2_142078_297142.pdf</a><sup> (1MB, pdf) </sup>
</div></div></section></section><section id="funding-statement1" lang="en"><h2 class="pmc_sec_title">Funding Statement</h2>
<p>This work was funded by Mallinckrodt Pharmaceuticals.</p></section><section id="ref-list1" class="ref-list"><h2 class="pmc_sec_title">References</h2>
<section id="ref-list1_sec2"><ul class="ref-list font-sm" style="list-style-type:none">
<li id="ref-476575">
<span class="label">1.</span><cite>Changing incidence of glomerular disease in Olmsted County, Minnesota: a 30-year renal biopsy study. Swaminathan S., Leung N., Lager D. J.., et al.  2006Clin J Am Soc Nephrol. 1(3):483–487. doi: 10.2215/CJN.00710805. <a href="https://doi.org/10.2215/CJN.00710805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.2215/CJN.00710805</a></cite> [<a href="https://doi.org/10.2215/CJN.00710805" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/17699249/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20J%20Am%20Soc%20Nephrol&amp;title=Changing%20incidence%20of%20glomerular%20disease%20in%20Olmsted%20County,%20Minnesota:%20a%2030-year%20renal%20biopsy%20study&amp;author=S.%20Swaminathan&amp;author=N.%20Leung&amp;author=D.%20J..%20Lager&amp;volume=1&amp;issue=3&amp;pages=483-487&amp;pmid=17699249&amp;doi=10.2215/CJN.00710805&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476576">
<span class="label">2.</span><cite>A pilot study to determine the dose and effectiveness of adrenocorticotrophic hormone (H.P. Acthar® Gel) in nephrotic syndrome due to idiopathic membranous nephropathy. Hladunewich M. A., Cattran D., Beck L. H.., et al.  2014Nephrol Dial Transplant. 29(8):1570–1577. doi: 10.1093/ndt/gfu069. <a href="https://doi.org/10.1093/ndt/gfu069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/ndt/gfu069</a></cite> [<a href="https://doi.org/10.1093/ndt/gfu069" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4106642/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24714414/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nephrol%20Dial%20Transplant&amp;title=A%20pilot%20study%20to%20determine%20the%20dose%20and%20effectiveness%20of%20adrenocorticotrophic%20hormone%20(H.P.%20Acthar%C2%AE%20Gel)%20in%20nephrotic%20syndrome%20due%20to%20idiopathic%20membranous%20nephropathy&amp;author=M.%20A.%20Hladunewich&amp;author=D.%20Cattran&amp;author=L.%20H..%20Beck&amp;volume=29&amp;issue=8&amp;pages=1570-1577&amp;pmid=24714414&amp;doi=10.1093/ndt/gfu069&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476577">
<span class="label">3.</span><cite>Idiopathic membranous nephropathy: definition and relevance of a partial remission. Troyanov S., Wall C. A., Miller J. A., Scholey J. W., Cattran D. C., Toronto Glomerulonephritis Registry Group  2004Kidney Int. 66(3):1199–1205. doi: 10.1111/j.1523-1755.2004.00873.x. <a href="https://doi.org/10.1111/j.1523-1755.2004.00873.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1111/j.1523-1755.2004.00873.x</a></cite> [<a href="https://doi.org/10.1111/j.1523-1755.2004.00873.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15327418/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=Idiopathic%20membranous%20nephropathy:%20definition%20and%20relevance%20of%20a%20partial%20remission&amp;author=S.%20Troyanov&amp;author=C.%20A.%20Wall&amp;author=J.%20A.%20Miller&amp;author=J.%20W.%20Scholey&amp;author=D.%20C.%20Cattran&amp;volume=66&amp;issue=3&amp;pages=1199-1205&amp;pmid=15327418&amp;doi=10.1111/j.1523-1755.2004.00873.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476578">
<span class="label">4.</span><cite>Disease-specific risk of venous thromboembolic events is increased in idiopathic glomerulonephritis. Barbour S. J., Greenwald A., Djurdjev O.., et al.  2012Kidney Int. 81(2):190–195. doi: 10.1038/ki.2011.312. <a href="https://doi.org/10.1038/ki.2011.312" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/ki.2011.312</a></cite> [<a href="https://doi.org/10.1038/ki.2011.312" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21918501/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=Disease-specific%20risk%20of%20venous%20thromboembolic%20events%20is%20increased%20in%20idiopathic%20glomerulonephritis&amp;author=S.%20J.%20Barbour&amp;author=A.%20Greenwald&amp;author=O..%20Djurdjev&amp;volume=81&amp;issue=2&amp;pages=190-195&amp;pmid=21918501&amp;doi=10.1038/ki.2011.312&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476579">
<span class="label">5.</span><cite>Spontaneous remission of nephrotic syndrome in idiopathic membranous nephropathy. Polanco N., Gutierrez E., Covarsi A.., et al.  2010J Am Soc Nephrol. 21(4):697–704. doi: 10.1681/ASN.2009080861. <a href="https://doi.org/10.1681/ASN.2009080861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1681/ASN.2009080861</a></cite> [<a href="https://doi.org/10.1681/ASN.2009080861" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2844306/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20110379/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Soc%20Nephrol&amp;title=Spontaneous%20remission%20of%20nephrotic%20syndrome%20in%20idiopathic%20membranous%20nephropathy&amp;author=N.%20Polanco&amp;author=E.%20Gutierrez&amp;author=A..%20Covarsi&amp;volume=21&amp;issue=4&amp;pages=697-704&amp;pmid=20110379&amp;doi=10.1681/ASN.2009080861&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476580">
<span class="label">6.</span><cite>KDIGO 2021 Clinical Practice Guideline for the Management of Glomerular Diseases. Kidney Disease: Improving Global Outcomes Glomerular Diseases Work Group  2021Kidney Int. 100(4S):S1–S276. doi: 10.1016/j.kint.2021.05.021. <a href="https://doi.org/10.1016/j.kint.2021.05.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.kint.2021.05.021</a></cite> [<a href="https://doi.org/10.1016/j.kint.2021.05.021" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34556256/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=KDIGO%202021%20Clinical%20Practice%20Guideline%20for%20the%20Management%20of%20Glomerular%20Diseases&amp;volume=100&amp;issue=4S&amp;pages=S1-S276&amp;pmid=34556256&amp;doi=10.1016/j.kint.2021.05.021&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476581">
<span class="label">7.</span><cite>Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Levey A. S., Cattran D., Friedman A.., et al.  2009Am J Kidney Dis. 54(2):205–226. doi: 10.1053/j.ajkd.2009.04.029. <a href="https://doi.org/10.1053/j.ajkd.2009.04.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1053/j.ajkd.2009.04.029</a></cite> [<a href="https://doi.org/10.1053/j.ajkd.2009.04.029" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/19577347/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Kidney%20Dis&amp;title=Proteinuria%20as%20a%20surrogate%20outcome%20in%20CKD:%20report%20of%20a%20scientific%20workshop%20sponsored%20by%20the%20National%20Kidney%20Foundation%20and%20the%20US%20Food%20and%20Drug%20Administration&amp;author=A.%20S.%20Levey&amp;author=D.%20Cattran&amp;author=A..%20Friedman&amp;volume=54&amp;issue=2&amp;pages=205-226&amp;pmid=19577347&amp;doi=10.1053/j.ajkd.2009.04.029&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476582">
<span class="label">8.</span><cite>Safety and efficacy of combination ACTHar Gel and tacrolimus in treatment-resistant focal segmental glomerulosclerosis and membranous glomerulopathy. Tumlin J., Galphin C., Santos R., Rovin B. 2017Kidney Int Rep. 2(5):924–932. doi: 10.1016/j.ekir.2017.05.015. <a href="https://doi.org/10.1016/j.ekir.2017.05.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.ekir.2017.05.015</a></cite> [<a href="https://doi.org/10.1016/j.ekir.2017.05.015" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5733765/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29270498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int%20Rep&amp;title=Safety%20and%20efficacy%20of%20combination%20ACTHar%20Gel%20and%20tacrolimus%20in%20treatment-resistant%20focal%20segmental%20glomerulosclerosis%20and%20membranous%20glomerulopathy&amp;author=J.%20Tumlin&amp;author=C.%20Galphin&amp;author=R.%20Santos&amp;author=B.%20Rovin&amp;volume=2&amp;issue=5&amp;pages=924-932&amp;pmid=29270498&amp;doi=10.1016/j.ekir.2017.05.015&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476583">
<span class="label">9.</span><cite>Treatment of primary FSGS in adults. Korbet S. M. 2012J Am Soc Nephrol. 23(11):1769–1776. doi: 10.1681/ASN.2012040389. <a href="https://doi.org/10.1681/ASN.2012040389" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1681/ASN.2012040389</a></cite> [<a href="https://doi.org/10.1681/ASN.2012040389" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22997260/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Soc%20Nephrol&amp;title=Treatment%20of%20primary%20FSGS%20in%20adults&amp;author=S.%20M.%20Korbet&amp;volume=23&amp;issue=11&amp;pages=1769-1776&amp;pmid=22997260&amp;doi=10.1681/ASN.2012040389&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476584">
<span class="label">10.</span><cite>Prevention and treatment of systemic glucocorticoid side effects. Moghadam-Kia S., Werth V. P. 2010Int J Dermatol. 49(3):239–248. doi: 10.1111/j.1365-4632.2009.04322.x. <a href="https://doi.org/10.1111/j.1365-4632.2009.04322.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1111/j.1365-4632.2009.04322.x</a></cite> [<a href="https://doi.org/10.1111/j.1365-4632.2009.04322.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2872100/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20465658/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Int%20J%20Dermatol&amp;title=Prevention%20and%20treatment%20of%20systemic%20glucocorticoid%20side%20effects&amp;author=S.%20Moghadam-Kia&amp;author=V.%20P.%20Werth&amp;volume=49&amp;issue=3&amp;pages=239-248&amp;pmid=20465658&amp;doi=10.1111/j.1365-4632.2009.04322.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476585">
<span class="label">11.</span><cite>Mallinckrodt Pharmaceuticals  Acthar® Gel prescribing information. 1952 (Revised October 2021) <a href="https://www.acthar.com/pdf/Acthar-PI.pdf" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.acthar.com/pdf/Acthar-PI.pdf</a></cite>
</li>
<li id="ref-476586">
<span class="label">12.</span><cite>Treatment of resistant glomerular diseases with adrenocorticotropic hormone gel: a prospective trial. Bomback A. S., Canetta P. A., Beck L. H., Jr., Ayalon R., Radhakrishnan J., Appel G. B. 2012Am J Nephrol. 36(1):58–67. doi: 10.1159/000339287. <a href="https://doi.org/10.1159/000339287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1159/000339287</a></cite> [<a href="https://doi.org/10.1159/000339287" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22722778/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Nephrol&amp;title=Treatment%20of%20resistant%20glomerular%20diseases%20with%20adrenocorticotropic%20hormone%20gel:%20a%20prospective%20trial&amp;author=A.%20S.%20Bomback&amp;author=P.%20A.%20Canetta&amp;author=L.%20H.,%20Jr.%20Beck&amp;author=R.%20Ayalon&amp;author=J.%20Radhakrishnan&amp;volume=36&amp;issue=1&amp;pages=58-67&amp;pmid=22722778&amp;doi=10.1159/000339287&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476587">
<span class="label">13.</span><cite>Treatment of nephrotic syndrome with adrenocorticotropic hormone (ACTH) gel. Bomback A. S., Tumlin J. A., Baranski J.., et al.  2011Drug Des Devel Ther. 5:147–153. doi: 10.2147/DDDT.S17521. <a href="https://doi.org/10.2147/DDDT.S17521" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.2147/DDDT.S17521</a></cite> [<a href="https://doi.org/10.2147/DDDT.S17521" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3063118/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21448451/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Drug%20Des%20Devel%20Ther&amp;title=Treatment%20of%20nephrotic%20syndrome%20with%20adrenocorticotropic%20hormone%20(ACTH)%20gel&amp;author=A.%20S.%20Bomback&amp;author=J.%20A.%20Tumlin&amp;author=J..%20Baranski&amp;volume=5&amp;pages=147-153&amp;pmid=21448451&amp;doi=10.2147/DDDT.S17521&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476588">
<span class="label">14.</span><cite>Acthar Gel in the treatment of nephrotic syndrome: a multicenter retrospective case series. Madan A., Mijovic-Das S., Stankovic A., Teehan G., Milward A.S., Khastgir A. 2016BMC Nephrol. 17:37. doi: 10.1186/s12882-016-0241-7. <a href="https://doi.org/10.1186/s12882-016-0241-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1186/s12882-016-0241-7</a></cite> [<a href="https://doi.org/10.1186/s12882-016-0241-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4815175/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27036111/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Nephrol&amp;title=Acthar%20Gel%20in%20the%20treatment%20of%20nephrotic%20syndrome:%20a%20multicenter%20retrospective%20case%20series&amp;author=A.%20Madan&amp;author=S.%20Mijovic-Das&amp;author=A.%20Stankovic&amp;author=G.%20Teehan&amp;author=A.S.%20Milward&amp;volume=17&amp;pages=37&amp;pmid=27036111&amp;doi=10.1186/s12882-016-0241-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476590">
<span class="label">15.</span><cite>Cyclophosphamide induced early remission and was superior to rituximab in idiopathic membranous nephropathy patients with high anti-PLA2R antibody levels. Xue C., Wang J., Pan J.., et al.  2023BMC Nephrol. 24(1):280. doi: 10.1186/s12882-023-03307-x. <a href="https://doi.org/10.1186/s12882-023-03307-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1186/s12882-023-03307-x</a></cite> [<a href="https://doi.org/10.1186/s12882-023-03307-x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10517553/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37740193/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Nephrol&amp;title=Cyclophosphamide%20induced%20early%20remission%20and%20was%20superior%20to%20rituximab%20in%20idiopathic%20membranous%20nephropathy%20patients%20with%20high%20anti-PLA2R%20antibody%20levels&amp;author=C.%20Xue&amp;author=J.%20Wang&amp;author=J..%20Pan&amp;volume=24&amp;issue=1&amp;pages=280&amp;pmid=37740193&amp;doi=10.1186/s12882-023-03307-x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476589">
<span class="label">16.</span><cite>Rituximab in idiopathic membranous nephropathy. Ruggenenti P., Cravedi P., Chianca A.., et al.  2012J Am Soc Nephrol. 23(8):1416–1425. doi: 10.1681/ASN.2012020181. <a href="https://doi.org/10.1681/ASN.2012020181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1681/ASN.2012020181</a></cite> [<a href="https://doi.org/10.1681/ASN.2012020181" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3402291/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22822077/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Soc%20Nephrol&amp;title=Rituximab%20in%20idiopathic%20membranous%20nephropathy&amp;author=P.%20Ruggenenti&amp;author=P.%20Cravedi&amp;author=A..%20Chianca&amp;volume=23&amp;issue=8&amp;pages=1416-1425&amp;pmid=22822077&amp;doi=10.1681/ASN.2012020181&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476591">
<span class="label">17.</span><cite>The STARMEN trial indicates that alternating treatment with corticosteroids and cyclophosphamide is superior to sequential treatment with tacrolimus and rituximab in primary membranous nephropathy. Fernández-Juárez G., Rojas-Rivera J., Logt A.-Evd.., et al.  2021Kidney Int. 99(4):986–998. doi: 10.1016/j.kint.2020.10.014. <a href="https://doi.org/10.1016/j.kint.2020.10.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.kint.2020.10.014</a></cite> [<a href="https://doi.org/10.1016/j.kint.2020.10.014" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33166580/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=The%20STARMEN%20trial%20indicates%20that%20alternating%20treatment%20with%20corticosteroids%20and%20cyclophosphamide%20is%20superior%20to%20sequential%20treatment%20with%20tacrolimus%20and%20rituximab%20in%20primary%20membranous%20nephropathy&amp;author=G.%20Fern%C3%A1ndez-Ju%C3%A1rez&amp;author=J.%20Rojas-Rivera&amp;author=A.-Evd..%20Logt&amp;volume=99&amp;issue=4&amp;pages=986-998&amp;pmid=33166580&amp;doi=10.1016/j.kint.2020.10.014&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476592">
<span class="label">18.</span><cite>Rituximab or cyclosporine in the treatment of membranous nephropathy. Fervenza F. C., Appel G. B., Barbour S. J.., et al.  2019N Engl J Med. 381(1):36–46. doi: 10.1056/NEJMoa1814427. <a href="https://doi.org/10.1056/NEJMoa1814427" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1056/NEJMoa1814427</a></cite> [<a href="https://doi.org/10.1056/NEJMoa1814427" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31269364/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=Rituximab%20or%20cyclosporine%20in%20the%20treatment%20of%20membranous%20nephropathy&amp;author=F.%20C.%20Fervenza&amp;author=G.%20B.%20Appel&amp;author=S.%20J..%20Barbour&amp;volume=381&amp;issue=1&amp;pages=36-46&amp;pmid=31269364&amp;doi=10.1056/NEJMoa1814427&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476597">
<span class="label">19.</span><cite>SA27 Reduction in corticosteroid use among patients with focal segmental glomerulosclerosis, membranous nephropathy, or IgA nephropathy after Acthar® Gel in a large administrative claims database. Hayes K., Hu F. S., Fahim M., Panaccio M., Niewoehner J., Wan G. J. 2024Value Health. 27(6):S400. doi: 10.1016/j.jval.2024.03.1874. <a href="https://doi.org/10.1016/j.jval.2024.03.1874" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.jval.2024.03.1874</a></cite> [<a href="https://doi.org/10.1016/j.jval.2024.03.1874" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Value%20Health&amp;title=SA27%20Reduction%20in%20corticosteroid%20use%20among%20patients%20with%20focal%20segmental%20glomerulosclerosis,%20membranous%20nephropathy,%20or%20IgA%20nephropathy%20after%20Acthar%C2%AE%20Gel%20in%20a%20large%20administrative%20claims%20database&amp;author=K.%20Hayes&amp;author=F.%20S.%20Hu&amp;author=M.%20Fahim&amp;author=M.%20Panaccio&amp;author=J.%20Niewoehner&amp;volume=27&amp;issue=6&amp;pages=S400&amp;doi=10.1016/j.jval.2024.03.1874&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476601">
<span class="label">20.</span><cite>Consequences of insurance denials among U.S. patients prescribed repository corticotropin injection (Acthar Gel) for nephrotic syndrome. Rice J. B., Panaccio M. P., White A.., et al.  2021Curr Med Res Opin. 37(3):431–441. doi: 10.1080/03007995.2021.1872515. <a href="https://doi.org/10.1080/03007995.2021.1872515" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1080/03007995.2021.1872515</a></cite> [<a href="https://doi.org/10.1080/03007995.2021.1872515" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33411573/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Curr%20Med%20Res%20Opin&amp;title=Consequences%20of%20insurance%20denials%20among%20U.S.%20patients%20prescribed%20repository%20corticotropin%20injection%20(Acthar%20Gel)%20for%20nephrotic%20syndrome&amp;author=J.%20B.%20Rice&amp;author=M.%20P.%20Panaccio&amp;author=A..%20White&amp;volume=37&amp;issue=3&amp;pages=431-441&amp;pmid=33411573&amp;doi=10.1080/03007995.2021.1872515&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476595">
<span class="label">21.</span><cite>The prevalence of pain among patients with chronic kidney disease using systematic review and meta-analysis. Lambourg E., Colvin L., Guthrie G.., et al.  2021Kidney Int. 100(3):636–649. doi: 10.1016/j.kint.2021.03.041. <a href="https://doi.org/10.1016/j.kint.2021.03.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.kint.2021.03.041</a></cite> [<a href="https://doi.org/10.1016/j.kint.2021.03.041" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33940112/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=The%20prevalence%20of%20pain%20among%20patients%20with%20chronic%20kidney%20disease%20using%20systematic%20review%20and%20meta-analysis&amp;author=E.%20Lambourg&amp;author=L.%20Colvin&amp;author=G..%20Guthrie&amp;volume=100&amp;issue=3&amp;pages=636-649&amp;pmid=33940112&amp;doi=10.1016/j.kint.2021.03.041&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476593">
<span class="label">22.</span><cite>The prevalence and lived experience of pain in people undertaking dialysis. Moore I., Byrne P., Ilic N., Chen J. H., Lambert K. 2023Kidney and Dialysis. 3(1):24–35. doi: 10.3390/kidneydial3010002. <a href="https://doi.org/10.3390/kidneydial3010002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.3390/kidneydial3010002</a></cite> [<a href="https://doi.org/10.3390/kidneydial3010002" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20and%20Dialysis&amp;title=The%20prevalence%20and%20lived%20experience%20of%20pain%20in%20people%20undertaking%20dialysis&amp;author=I.%20Moore&amp;author=P.%20Byrne&amp;author=N.%20Ilic&amp;author=J.%20H.%20Chen&amp;author=K.%20Lambert&amp;volume=3&amp;issue=1&amp;pages=24-35&amp;doi=10.3390/kidneydial3010002&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476596">
<span class="label">23.</span><cite>Depression in chronic kidney disease and end-stage renal disease: similarities and differences in diagnosis, epidemiology, and management. Shirazian S., Grant C. D., Aina O., Mattana J., Khorassani F., Ricardo A. C. 2017Kidney Int Rep. 2(1):94–107. doi: 10.1016/j.ekir.2016.09.005. <a href="https://doi.org/10.1016/j.ekir.2016.09.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.ekir.2016.09.005</a></cite> [<a href="https://doi.org/10.1016/j.ekir.2016.09.005" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC5720531/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29318209/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int%20Rep&amp;title=Depression%20in%20chronic%20kidney%20disease%20and%20end-stage%20renal%20disease:%20similarities%20and%20differences%20in%20diagnosis,%20epidemiology,%20and%20management&amp;author=S.%20Shirazian&amp;author=C.%20D.%20Grant&amp;author=O.%20Aina&amp;author=J.%20Mattana&amp;author=F.%20Khorassani&amp;volume=2&amp;issue=1&amp;pages=94-107&amp;pmid=29318209&amp;doi=10.1016/j.ekir.2016.09.005&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476602">
<span class="label">24.</span><cite>A national registry study of patient and renal survival in adult nephrotic syndrome. Kolb A., Gallacher P. J., Campbell J.., et al.  2021Kidney Int Rep. 6(2):449–459. doi: 10.1016/j.ekir.2020.10.033. <a href="https://doi.org/10.1016/j.ekir.2020.10.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.ekir.2020.10.033</a></cite> [<a href="https://doi.org/10.1016/j.ekir.2020.10.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7879209/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/33615070/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int%20Rep&amp;title=A%20national%20registry%20study%20of%20patient%20and%20renal%20survival%20in%20adult%20nephrotic%20syndrome&amp;author=A.%20Kolb&amp;author=P.%20J.%20Gallacher&amp;author=J..%20Campbell&amp;volume=6&amp;issue=2&amp;pages=449-459&amp;pmid=33615070&amp;doi=10.1016/j.ekir.2020.10.033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476603">
<span class="label">25.</span><cite>Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis. Coca S.G., Singanamala S., Parikh C.R. 2012Kidney Int. 81(5):442–448. doi: 10.1038/ki.2011.379. <a href="https://doi.org/10.1038/ki.2011.379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/ki.2011.379</a></cite> [<a href="https://doi.org/10.1038/ki.2011.379" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3788581/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22113526/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=Chronic%20kidney%20disease%20after%20acute%20kidney%20injury:%20a%20systematic%20review%20and%20meta-analysis&amp;author=S.G.%20Coca&amp;author=S.%20Singanamala&amp;author=C.R.%20Parikh&amp;volume=81&amp;issue=5&amp;pages=442-448&amp;pmid=22113526&amp;doi=10.1038/ki.2011.379&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476604">
<span class="label">26.</span><cite>National Institute of Diabetes and Digestive and Kidney Diseases  United States Renal Data System. <a href="https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality" class="usa-link" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://usrds-adr.niddk.nih.gov/2024/end-stage-renal-disease/6-mortality</a></cite>
</li>
<li id="ref-476605">
<span class="label">27.</span><cite>Merative L.P.  Micromedex® Red Book®. <a href="https://www.merative.com/documents/micromedex-red-book" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.merative.com/documents/micromedex-red-book</a></cite>
</li>
<li id="ref-476618">
<span class="label">28.</span><cite>Plasma exchange versus intravenous immunoglobulin for myasthenia gravis crisis: an acute hospital cost comparison study. Heatwole C., Johnson N., Holloway R., Noyes K. 2011J Clin Neuromuscul Dis. 13(2):85–94. doi: 10.1097/CND.0b013e31822c34dd. <a href="https://doi.org/10.1097/CND.0b013e31822c34dd" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1097/CND.0b013e31822c34dd</a></cite> [<a href="https://doi.org/10.1097/CND.0b013e31822c34dd" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3291869/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/22361692/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Clin%20Neuromuscul%20Dis&amp;title=Plasma%20exchange%20versus%20intravenous%20immunoglobulin%20for%20myasthenia%20gravis%20crisis:%20an%20acute%20hospital%20cost%20comparison%20study&amp;author=C.%20Heatwole&amp;author=N.%20Johnson&amp;author=R.%20Holloway&amp;author=K.%20Noyes&amp;volume=13&amp;issue=2&amp;pages=85-94&amp;pmid=22361692&amp;doi=10.1097/CND.0b013e31822c34dd&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476616">
<span class="label">29.</span><cite>Cost-minimization analysis of the direct costs of TPE and IVIg in the treatment of Guillain-Barre syndrome. Winters J. L., Brown D., Hazard E., Chainani A., Andrzejewski C., Jr. 2011BMC Health Serv Res. 11:101. doi: 10.1186/1472-6963-11-101. <a href="https://doi.org/10.1186/1472-6963-11-101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1186/1472-6963-11-101</a></cite> [<a href="https://doi.org/10.1186/1472-6963-11-101" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC3121582/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21575219/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Health%20Serv%20Res&amp;title=Cost-minimization%20analysis%20of%20the%20direct%20costs%20of%20TPE%20and%20IVIg%20in%20the%20treatment%20of%20Guillain-Barre%20syndrome&amp;author=J.%20L.%20Winters&amp;author=D.%20Brown&amp;author=E.%20Hazard&amp;author=A.%20Chainani&amp;author=C.,%20Jr.%20Andrzejewski&amp;volume=11&amp;pages=101&amp;pmid=21575219&amp;doi=10.1186/1472-6963-11-101&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476617">
<span class="label">30.</span><cite>US Bureau of Labor Statistics  Occupational Employment and Wage Statistics.  [2025-1-20]. <a href="https://www.bls.gov/oes/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.bls.gov/oes/</a></cite>
</li>
<li id="ref-476619">
<span class="label">31.</span><cite>Cost-effectiveness of nonsteroidal anti-inflammatory drugs and opioids in the treatment of knee osteoarthritis in older patients with multiple comorbidities. Katz J. N., Smith S. R., Collins J. E.., et al.  2016Osteoarthritis Cartilage. 24(3):409–418. doi: 10.1016/j.joca.2015.10.006. <a href="https://doi.org/10.1016/j.joca.2015.10.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.joca.2015.10.006</a></cite> [<a href="https://doi.org/10.1016/j.joca.2015.10.006" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4761310/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26525846/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Osteoarthritis%20Cartilage&amp;title=Cost-effectiveness%20of%20nonsteroidal%20anti-inflammatory%20drugs%20and%20opioids%20in%20the%20treatment%20of%20knee%20osteoarthritis%20in%20older%20patients%20with%20multiple%20comorbidities&amp;author=J.%20N.%20Katz&amp;author=S.%20R.%20Smith&amp;author=J.%20E..%20Collins&amp;volume=24&amp;issue=3&amp;pages=409-418&amp;pmid=26525846&amp;doi=10.1016/j.joca.2015.10.006&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476620">
<span class="label">32.</span><cite>Total expenses, total utilization, and sources of payment for outpatient prescription opioids in the U.S. adult civilian noninstitutionalized population, 2017. Ding Y., Miller G. E. 2001Statistical Brief (Medical Expenditure Panel Survey (US)) </cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/35696499/" class="usa-link">PubMed</a>]</li>
<li id="ref-476626">
<span class="label">33.</span><cite>Cost of prescribed NSAID-related gastrointestinal adverse events in elderly patients. Rahme E., Joseph L., Kong S.X., Watson D.J., LeLorier J. 2001Br J Clin Pharmacol. 52(2):185–192. doi: 10.1046/j.1365-2125.2001.00348.x. <a href="https://doi.org/10.1046/j.1365-2125.2001.00348.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1046/j.1365-2125.2001.00348.x</a></cite> [<a href="https://doi.org/10.1046/j.1365-2125.2001.00348.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2014523/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/11488776/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Clin%20Pharmacol&amp;title=Cost%20of%20prescribed%20NSAID-related%20gastrointestinal%20adverse%20events%20in%20elderly%20patients&amp;author=E.%20Rahme&amp;author=L.%20Joseph&amp;author=S.X.%20Kong&amp;author=D.J.%20Watson&amp;author=J.%20LeLorier&amp;volume=52&amp;issue=2&amp;pages=185-192&amp;pmid=11488776&amp;doi=10.1046/j.1365-2125.2001.00348.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476627">
<span class="label">34.</span><cite>Direct costs of opioid abuse in an insured population in the United States. White A. G., Birnbaum H. G., Mareva M. N.., et al.  2005J Manag Care Pharm. 11(6):469–479. doi: 10.18553/jmcp.2005.11.6.469. <a href="https://doi.org/10.18553/jmcp.2005.11.6.469" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.18553/jmcp.2005.11.6.469</a></cite> [<a href="https://doi.org/10.18553/jmcp.2005.11.6.469" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10437436/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/15998164/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Manag%20Care%20Pharm&amp;title=Direct%20costs%20of%20opioid%20abuse%20in%20an%20insured%20population%20in%20the%20United%20States&amp;author=A.%20G.%20White&amp;author=H.%20G.%20Birnbaum&amp;author=M.%20N..%20Mareva&amp;volume=11&amp;issue=6&amp;pages=469-479&amp;pmid=15998164&amp;doi=10.18553/jmcp.2005.11.6.469&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476628">
<span class="label">35.</span><cite>Caring for people with depression: costs among 43 million commercially insured patients with or without comorbid illnesses. Glassman J. R., Jauregui A., Milstein A., Kaplan R. M. 2023Ann Behav Med. 57(5):380–385. doi: 10.1093/abm/kaac063. <a href="https://doi.org/10.1093/abm/kaac063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/abm/kaac063</a></cite> [<a href="https://doi.org/10.1093/abm/kaac063" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37001050/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Behav%20Med&amp;title=Caring%20for%20people%20with%20depression:%20costs%20among%2043%20million%20commercially%20insured%20patients%20with%20or%20without%20comorbid%20illnesses&amp;author=J.%20R.%20Glassman&amp;author=A.%20Jauregui&amp;author=A.%20Milstein&amp;author=R.%20M.%20Kaplan&amp;volume=57&amp;issue=5&amp;pages=380-385&amp;pmid=37001050&amp;doi=10.1093/abm/kaac063&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476611">
<span class="label">36.</span><cite>Patients with idiopathic membranous nephropathy: a real-world clinical and economic analysis of U.S. claims data. Nazareth T. A., Kariburyo F., Kirkemo A.., et al.  2019J Manag Care Spec Pharm. 25(9):1011–1020. doi: 10.18553/jmcp.2019.18456. <a href="https://doi.org/10.18553/jmcp.2019.18456" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.18553/jmcp.2019.18456</a></cite> [<a href="https://doi.org/10.18553/jmcp.2019.18456" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10397828/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/31283419/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Manag%20Care%20Spec%20Pharm&amp;title=Patients%20with%20idiopathic%20membranous%20nephropathy:%20a%20real-world%20clinical%20and%20economic%20analysis%20of%20U.S.%20claims%20data&amp;author=T.%20A.%20Nazareth&amp;author=F.%20Kariburyo&amp;author=A..%20Kirkemo&amp;volume=25&amp;issue=9&amp;pages=1011-1020&amp;pmid=31283419&amp;doi=10.18553/jmcp.2019.18456&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476633">
<span class="label">37.</span><cite>Hemodialysis versus peritoneal dialysis drug expenditures: a comparison within the private insurance market. Bhatnagar A., Niu J., Ho V., Winkelmayer W.C., Erickson K.F. 2023Kidney Med. 5(8):100678. doi: 10.1016/j.xkme.2023.100678. <a href="https://doi.org/10.1016/j.xkme.2023.100678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.xkme.2023.100678</a></cite> [<a href="https://doi.org/10.1016/j.xkme.2023.100678" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10344940/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37455793/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Med&amp;title=Hemodialysis%20versus%20peritoneal%20dialysis%20drug%20expenditures:%20a%20comparison%20within%20the%20private%20insurance%20market&amp;author=A.%20Bhatnagar&amp;author=J.%20Niu&amp;author=V.%20Ho&amp;author=W.C.%20Winkelmayer&amp;author=K.F.%20Erickson&amp;volume=5&amp;issue=8&amp;pages=100678&amp;pmid=37455793&amp;doi=10.1016/j.xkme.2023.100678&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476634">
<span class="label">38.</span><cite>Bentley T. S., Ortner N. 2020 U.S. organ and tissue transplants: cost estimates, discussion, and emerging issues.  [2025-12-3]. <a href="https://www.milliman.com/en/insight/2020-us-organ-and-tissue-transplants" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://www.milliman.com/en/insight/2020-us-organ-and-tissue-transplants</a></cite>
</li>
<li id="ref-476629">
<span class="label">39.</span><cite>Global economic burden associated with chronic kidney disease: a pragmatic review of medical costs for the inside CKD Research Programme. Jha V., Al-Ghamdi S. M. G., Li G.., et al.  2023Adv Ther. 40(10):4405–4420. doi: 10.1007/s12325-023-02608-9. <a href="https://doi.org/10.1007/s12325-023-02608-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1007/s12325-023-02608-9</a></cite> [<a href="https://doi.org/10.1007/s12325-023-02608-9" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10499937/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37493856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Adv%20Ther&amp;title=Global%20economic%20burden%20associated%20with%20chronic%20kidney%20disease:%20a%20pragmatic%20review%20of%20medical%20costs%20for%20the%20inside%20CKD%20Research%20Programme&amp;author=V.%20Jha&amp;author=S.%20M.%20G.%20Al-Ghamdi&amp;author=G..%20Li&amp;volume=40&amp;issue=10&amp;pages=4405-4420&amp;pmid=37493856&amp;doi=10.1007/s12325-023-02608-9&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476630">
<span class="label">40.</span><cite>End-of-life medical spending in last twelve months of life is lower than previously reported. French E. B., McCauley J., Aragon M.., et al.  2017Health Aff (Millwood) 36(7):1211–1217. doi: 10.1377/hlthaff.2017.0174. <a href="https://doi.org/10.1377/hlthaff.2017.0174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1377/hlthaff.2017.0174</a></cite> [<a href="https://doi.org/10.1377/hlthaff.2017.0174" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28679807/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Health%20Aff%20(Millwood)&amp;title=End-of-life%20medical%20spending%20in%20last%20twelve%20months%20of%20life%20is%20lower%20than%20previously%20reported&amp;author=E.%20B.%20French&amp;author=J.%20McCauley&amp;author=M..%20Aragon&amp;volume=36&amp;issue=7&amp;pages=1211-1217&amp;pmid=28679807&amp;doi=10.1377/hlthaff.2017.0174&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476640">
<span class="label">41.</span><cite>Cost of neutropenic complications of chemotherapy. Weycker D., Malin J., Edelsberg J., Glass A., Gokhale M., Oster G. 2008Ann Oncol. 19(3):454–460. doi: 10.1093/annonc/mdm525. <a href="https://doi.org/10.1093/annonc/mdm525" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/annonc/mdm525</a></cite> [<a href="https://doi.org/10.1093/annonc/mdm525" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/18083689/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Cost%20of%20neutropenic%20complications%20of%20chemotherapy&amp;author=D.%20Weycker&amp;author=J.%20Malin&amp;author=J.%20Edelsberg&amp;author=A.%20Glass&amp;author=M.%20Gokhale&amp;volume=19&amp;issue=3&amp;pages=454-460&amp;pmid=18083689&amp;doi=10.1093/annonc/mdm525&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476641">
<span class="label">42.</span><cite>The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs. Grosse S. D., Nelson R. E., Nyarko K. A., Richardson L. C., Raskob G. E. 2016Thromb Res. 137:3–10. doi: 10.1016/j.thromres.2015.11.033. <a href="https://doi.org/10.1016/j.thromres.2015.11.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.thromres.2015.11.033</a></cite> [<a href="https://doi.org/10.1016/j.thromres.2015.11.033" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4706477/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/26654719/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Thromb%20Res&amp;title=The%20economic%20burden%20of%20incident%20venous%20thromboembolism%20in%20the%20United%20States:%20a%20review%20of%20estimated%20attributable%20healthcare%20costs&amp;author=S.%20D.%20Grosse&amp;author=R.%20E.%20Nelson&amp;author=K.%20A.%20Nyarko&amp;author=L.%20C.%20Richardson&amp;author=G.%20E.%20Raskob&amp;volume=137&amp;pages=3-10&amp;pmid=26654719&amp;doi=10.1016/j.thromres.2015.11.033&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476639">
<span class="label">43.</span><cite>Owens P. L., Miller M. A., Barrett M. L., Hensche M.  Overview of outcomes for inpatient stays involving sepsis, 2016-2021. Agency for Healthcare Research and Quality; Rockville, MD: </cite> [<a href="https://scholar.google.com/scholar_lookup?title=Overview%20of%20outcomes%20for%20inpatient%20stays%20involving%20sepsis,%202016-2021&amp;author=P.%20L.%20Owens&amp;author=M.%20A.%20Miller&amp;author=M.%20L.%20Barrett&amp;author=M.%20Hensche&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476635">
<span class="label">44.</span><cite>Clinical and economic impact of infusion reactions in patients with colorectal cancer treated with cetuximab. Foley K. A., Wang P. F., Barber B. L.., et al.  2010Ann Oncol. 21(7):1455–1461. doi: 10.1093/annonc/mdp535. <a href="https://doi.org/10.1093/annonc/mdp535" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/annonc/mdp535</a></cite> [<a href="https://doi.org/10.1093/annonc/mdp535" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2890318/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/20100773/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ann%20Oncol&amp;title=Clinical%20and%20economic%20impact%20of%20infusion%20reactions%20in%20patients%20with%20colorectal%20cancer%20treated%20with%20cetuximab&amp;author=K.%20A.%20Foley&amp;author=P.%20F.%20Wang&amp;author=B.%20L..%20Barber&amp;volume=21&amp;issue=7&amp;pages=1455-1461&amp;pmid=20100773&amp;doi=10.1093/annonc/mdp535&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476637">
<span class="label">45.</span><cite>Hospitalization costs for acute myocardial infarction patients treated with percutaneous coronary intervention in the United States are substantially higher than Medicare payments. Afana M., Brinjikji W., Cloft H., Salka S. 2015Clin Cardiol. 38(1):13–19. doi: 10.1002/clc.22341. <a href="https://doi.org/10.1002/clc.22341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1002/clc.22341</a></cite> [<a href="https://doi.org/10.1002/clc.22341" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6711053/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/25336401/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Cardiol&amp;title=Hospitalization%20costs%20for%20acute%20myocardial%20infarction%20patients%20treated%20with%20percutaneous%20coronary%20intervention%20in%20the%20United%20States%20are%20substantially%20higher%20than%20Medicare%20payments&amp;author=M.%20Afana&amp;author=W.%20Brinjikji&amp;author=H.%20Cloft&amp;author=S.%20Salka&amp;volume=38&amp;issue=1&amp;pages=13-19&amp;pmid=25336401&amp;doi=10.1002/clc.22341&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476636">
<span class="label">46.</span><cite>Diabetes-related inpatient stays, 2018. Fingar K. R., Reid L. D. 2006Healthcare Cost and Utilization Project (HCUP) Statistical Briefs. </cite>
</li>
<li id="ref-476638">
<span class="label">47.</span><cite>A systematic review of the costs of drug-associated acute kidney injury and potential cost savings with nephrotoxin stewardship prevention strategies. Stottlemyer B. A., Tran T., Suh K., Kane-Gill S. L. 2024Clin Pharmacol Ther.  doi: 10.1002/cpt.3493. <a href="https://doi.org/10.1002/cpt.3493" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1002/cpt.3493</a></cite> [<a href="https://doi.org/10.1002/cpt.3493" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC11924149/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/39535321/" class="usa-link">PubMed</a>]</li>
<li id="ref-476642">
<span class="label">48.</span><cite>Healthcare resource use and cost associated with varying dosages of extended corticosteroid exposure in a US population. Rice J. B., White A. G., Johnson M.., et al.  2018J Med Econ. 21(9):846–852. doi: 10.1080/13696998.2018.1474750. <a href="https://doi.org/10.1080/13696998.2018.1474750" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1080/13696998.2018.1474750</a></cite> [<a href="https://doi.org/10.1080/13696998.2018.1474750" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29741439/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Med%20Econ&amp;title=Healthcare%20resource%20use%20and%20cost%20associated%20with%20varying%20dosages%20of%20extended%20corticosteroid%20exposure%20in%20a%20US%20population&amp;author=J.%20B.%20Rice&amp;author=A.%20G.%20White&amp;author=M..%20Johnson&amp;volume=21&amp;issue=9&amp;pages=846-852&amp;pmid=29741439&amp;doi=10.1080/13696998.2018.1474750&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476594">
<span class="label">49.</span><cite>Prevalence and severity of pain in adult end-stage renal disease patients on chronic intermittent hemodialysis: a systematic review. Brkovic T., Burilovic E., Puljak L. 2016Patient Prefer Adherence. 10:1131–1150. doi: 10.2147/PPA.S103927. <a href="https://doi.org/10.2147/PPA.S103927" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.2147/PPA.S103927</a></cite> [<a href="https://doi.org/10.2147/PPA.S103927" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4922783/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27382261/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Patient%20Prefer%20Adherence&amp;title=Prevalence%20and%20severity%20of%20pain%20in%20adult%20end-stage%20renal%20disease%20patients%20on%20chronic%20intermittent%20hemodialysis:%20a%20systematic%20review&amp;author=T.%20Brkovic&amp;author=E.%20Burilovic&amp;author=L.%20Puljak&amp;volume=10&amp;pages=1131-1150&amp;pmid=27382261&amp;doi=10.2147/PPA.S103927&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476598">
<span class="label">50.</span><cite>Diagnosis and management of nephrotic syndrome in adults. Kodner C. 2016Am Fam Physician. 93(6):479–485.</cite> [<a href="https://pubmed.ncbi.nlm.nih.gov/26977832/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20Fam%20Physician&amp;title=Diagnosis%20and%20management%20of%20nephrotic%20syndrome%20in%20adults&amp;author=C.%20Kodner&amp;volume=93&amp;issue=6&amp;pages=479-485&amp;pmid=26977832&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476599">
<span class="label">51.</span><cite>Primary nephrotic syndrome and risks of ESKD, cardiovascular events, and death: the Kaiser Permanente Nephrotic Syndrome Study. Go A.S., Tan T.C., Chertow G.M.., et al.  2021J Am Soc Nephrol. 32(9):2303–2314. doi: 10.1681/ASN.2020111583. <a href="https://doi.org/10.1681/ASN.2020111583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1681/ASN.2020111583</a></cite> [<a href="https://doi.org/10.1681/ASN.2020111583" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC8729848/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34362836/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=J%20Am%20Soc%20Nephrol&amp;title=Primary%20nephrotic%20syndrome%20and%20risks%20of%20ESKD,%20cardiovascular%20events,%20and%20death:%20the%20Kaiser%20Permanente%20Nephrotic%20Syndrome%20Study&amp;author=A.S.%20Go&amp;author=T.C.%20Tan&amp;author=G.M..%20Chertow&amp;volume=32&amp;issue=9&amp;pages=2303-2314&amp;pmid=34362836&amp;doi=10.1681/ASN.2020111583&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476600">
<span class="label">52.</span><cite>The increased risk of coronary heart disease associated with nephrotic syndrome. Ordonez J. D., Hiatt R. A., Killebrew E. J., Fireman B. H. 1993Kidney Int. 44(3):638–242. doi: 10.1038/ki.1993.292. <a href="https://doi.org/10.1038/ki.1993.292" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/ki.1993.292</a></cite> [<a href="https://doi.org/10.1038/ki.1993.292" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/8231039/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Kidney%20Int&amp;title=The%20increased%20risk%20of%20coronary%20heart%20disease%20associated%20with%20nephrotic%20syndrome&amp;author=J.%20D.%20Ordonez&amp;author=R.%20A.%20Hiatt&amp;author=E.%20J.%20Killebrew&amp;author=B.%20H.%20Fireman&amp;volume=44&amp;issue=3&amp;pages=638-242&amp;pmid=8231039&amp;doi=10.1038/ki.1993.292&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476606">
<span class="label">53.</span><cite>Repetitive administration of rituximab can achieve and maintain clinical remission in patients with MCD or FSGS. Osterholt T., Todorova P., Kuhne L.., et al.  2023Sci Rep. 13(1):6980. doi: 10.1038/s41598-023-32576-7. <a href="https://doi.org/10.1038/s41598-023-32576-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1038/s41598-023-32576-7</a></cite> [<a href="https://doi.org/10.1038/s41598-023-32576-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC10141841/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37117201/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Sci%20Rep&amp;title=Repetitive%20administration%20of%20rituximab%20can%20achieve%20and%20maintain%20clinical%20remission%20in%20patients%20with%20MCD%20or%20FSGS&amp;author=T.%20Osterholt&amp;author=P.%20Todorova&amp;author=L..%20Kuhne&amp;volume=13&amp;issue=1&amp;pages=6980&amp;pmid=37117201&amp;doi=10.1038/s41598-023-32576-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476607">
<span class="label">54.</span><cite>Costs of providing infusion therapy for rheumatoid arthritis in a hospital-based infusion center setting. Schmier J., Ogden K., Nickman N.., et al.  2017Clin Ther. 39(8):1600–1617. doi: 10.1016/j.clinthera.2017.06.007. <a href="https://doi.org/10.1016/j.clinthera.2017.06.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.clinthera.2017.06.007</a></cite> [<a href="https://doi.org/10.1016/j.clinthera.2017.06.007" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/28716293/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Ther&amp;title=Costs%20of%20providing%20infusion%20therapy%20for%20rheumatoid%20arthritis%20in%20a%20hospital-based%20infusion%20center%20setting&amp;author=J.%20Schmier&amp;author=K.%20Ogden&amp;author=N..%20Nickman&amp;volume=39&amp;issue=8&amp;pages=1600-1617&amp;pmid=28716293&amp;doi=10.1016/j.clinthera.2017.06.007&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476608">
<span class="label">55.</span><cite>Cost-effectiveness of prophylaxis against Pneumocystis carinii pneumonia in patients with Wegner's granulomatosis undergoing immunosuppressive therapy. Chung J. B., Armstrong K., Schwartz J. S., Albert D. 2000Arthritis Rheum. 43(8):1841–1848. doi: 10.1002/1529-0131(200008)43:8&amp;#x0003c;1841::AID-ANR21&amp;#x0003e;3.0.CO;2-Q.</cite> [<a href="https://doi.org/10.1002/1529-0131(200008)43:8&amp;#x0003c;1841::AID-ANR21&amp;#x0003e;3.0.CO;2-Q" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/10943875/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Arthritis%20Rheum&amp;title=Cost-effectiveness%20of%20prophylaxis%20against%20Pneumocystis%20carinii%20pneumonia%20in%20patients%20with%20Wegner's%20granulomatosis%20undergoing%20immunosuppressive%20therapy&amp;author=J.%20B.%20Chung&amp;author=K.%20Armstrong&amp;author=J.%20S.%20Schwartz&amp;author=D.%20Albert&amp;volume=43&amp;issue=8&amp;pages=1841-1848&amp;pmid=10943875&amp;doi=10.1002/1529-0131(200008)43:8&amp;#x0003c;1841::AID-ANR21&amp;#x0003e;3.0.CO;2-Q&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476609">
<span class="label">56.</span><cite>Financial burden of drugs prescribed for cancer-associated symptoms. Gupta A., Nshuti L., Grewal U. S.., et al.  2022JCO Oncol Pract. 18(2):140–147. doi: 10.1200/OP.21.00466. <a href="https://doi.org/10.1200/OP.21.00466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1200/OP.21.00466</a></cite> [<a href="https://doi.org/10.1200/OP.21.00466" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9213200/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34558297/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=JCO%20Oncol%20Pract&amp;title=Financial%20burden%20of%20drugs%20prescribed%20for%20cancer-associated%20symptoms&amp;author=A.%20Gupta&amp;author=L.%20Nshuti&amp;author=U.%20S..%20Grewal&amp;volume=18&amp;issue=2&amp;pages=140-147&amp;pmid=34558297&amp;doi=10.1200/OP.21.00466&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476610">
<span class="label">57.</span><cite>US Bureau of Labor Statistics  CPI for all urban consumers. Medical care in U.S. city average, all urban consumers, seasonally adjusted. <a href="https://data.bls.gov/" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://data.bls.gov/</a></cite>
</li>
<li id="ref-476612">
<span class="label">58.</span><cite>Tacrolimus therapy in adult-onset steroid-resistant nephrotic syndrome due to a focal segmental glomerulosclerosis single-center experience. Ramachandran R., Kumar V., Rathi M.., et al.  2014Nephrol Dial Transplant. 29(10):1918–1924. doi: 10.1093/ndt/gfu097. <a href="https://doi.org/10.1093/ndt/gfu097" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/ndt/gfu097</a></cite> [<a href="https://doi.org/10.1093/ndt/gfu097" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/24771498/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Nephrol%20Dial%20Transplant&amp;title=Tacrolimus%20therapy%20in%20adult-onset%20steroid-resistant%20nephrotic%20syndrome%20due%20to%20a%20focal%20segmental%20glomerulosclerosis%20single-center%20experience&amp;author=R.%20Ramachandran&amp;author=V.%20Kumar&amp;author=M..%20Rathi&amp;volume=29&amp;issue=10&amp;pages=1918-1924&amp;pmid=24771498&amp;doi=10.1093/ndt/gfu097&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476613">
<span class="label">59.</span><cite>Patients with nephrotic syndrome (NS) receiving repository corticotropin injection (RCI) or rituximab (RTX): real-world (RW) evidence from a US claims analysis. Nazareth T., Kariburyo F., Pirani A.., et al.  2017Am J Kidney Dis. 69(4):A69. doi: 10.1053/j.ajkd.2017.02.219. <a href="https://doi.org/10.1053/j.ajkd.2017.02.219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1053/j.ajkd.2017.02.219</a></cite> [<a href="https://doi.org/10.1053/j.ajkd.2017.02.219" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Kidney%20Dis&amp;title=Patients%20with%20nephrotic%20syndrome%20(NS)%20receiving%20repository%20corticotropin%20injection%20(RCI)%20or%20rituximab%20(RTX):%20real-world%20(RW)%20evidence%20from%20a%20US%20claims%20analysis&amp;author=T.%20Nazareth&amp;author=F.%20Kariburyo&amp;author=A..%20Pirani&amp;volume=69&amp;issue=4&amp;pages=A69&amp;doi=10.1053/j.ajkd.2017.02.219&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476614">
<span class="label">60.</span><cite>The role of plasma exchange in treating post-transplant focal segmental glomerulosclerosis: a systematic review and meta-analysis of 77 case-reports and case-series. Kashgary A., Sontrop J. M., Li L.., et al.  2016BMC Nephrol. 17(1):104. doi: 10.1186/s12882-016-0322-7. <a href="https://doi.org/10.1186/s12882-016-0322-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1186/s12882-016-0322-7</a></cite> [<a href="https://doi.org/10.1186/s12882-016-0322-7" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC4966699/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/27473582/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Nephrol&amp;title=The%20role%20of%20plasma%20exchange%20in%20treating%20post-transplant%20focal%20segmental%20glomerulosclerosis:%20a%20systematic%20review%20and%20meta-analysis%20of%2077%20case-reports%20and%20case-series&amp;author=A.%20Kashgary&amp;author=J.%20M.%20Sontrop&amp;author=L..%20Li&amp;volume=17&amp;issue=1&amp;pages=104&amp;pmid=27473582&amp;doi=10.1186/s12882-016-0322-7&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476615">
<span class="label">61.</span><cite>Cost-minimisation analysis of plasma exchange versus IVIg in the treatment of autoimmune neurological conditions. Klemencic Kozul T., Yudina A., Donovan C., Pinto A., Osman C. 2022BMC Health Serv Res. 22(1):904. doi: 10.1186/s12913-022-08210-z. <a href="https://doi.org/10.1186/s12913-022-08210-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1186/s12913-022-08210-z</a></cite> [<a href="https://doi.org/10.1186/s12913-022-08210-z" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC9277970/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/35831856/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=BMC%20Health%20Serv%20Res&amp;title=Cost-minimisation%20analysis%20of%20plasma%20exchange%20versus%20IVIg%20in%20the%20treatment%20of%20autoimmune%20neurological%20conditions&amp;author=T.%20Klemencic%20Kozul&amp;author=A.%20Yudina&amp;author=C.%20Donovan&amp;author=A.%20Pinto&amp;author=C.%20Osman&amp;volume=22&amp;issue=1&amp;pages=904&amp;pmid=35831856&amp;doi=10.1186/s12913-022-08210-z&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476621">
<span class="label">62.</span><cite>Non-steroidal anti-inflammatory drugs in chronic kidney disease: a systematic review of prescription practices and use in primary care. Lefebvre C., Hindie J., Zappitelli M., Platt R. W., Filion K. B. 2020Clin Kidney J. 13(1):63–71. doi: 10.1093/ckj/sfz054. <a href="https://doi.org/10.1093/ckj/sfz054" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1093/ckj/sfz054</a></cite> [<a href="https://doi.org/10.1093/ckj/sfz054" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7025355/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32082554/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Clin%20Kidney%20J&amp;title=Non-steroidal%20anti-inflammatory%20drugs%20in%20chronic%20kidney%20disease:%20a%20systematic%20review%20of%20prescription%20practices%20and%20use%20in%20primary%20care&amp;author=C.%20Lefebvre&amp;author=J.%20Hindie&amp;author=M.%20Zappitelli&amp;author=R.%20W.%20Platt&amp;author=K.%20B.%20Filion&amp;volume=13&amp;issue=1&amp;pages=63-71&amp;pmid=32082554&amp;doi=10.1093/ckj/sfz054&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476622">
<span class="label">63.</span><cite>Analgesic use and associated adverse events in patients with chronic kidney disease: a systematic review and meta-analysis. Lambourg E., Colvin L., Guthrie G., Walker H., Bell S. 2022Br J Anaesth. 128(3):546–561. doi: 10.1016/j.bja.2021.08.035. <a href="https://doi.org/10.1016/j.bja.2021.08.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.bja.2021.08.035</a></cite> [<a href="https://doi.org/10.1016/j.bja.2021.08.035" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/34763813/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Br%20J%20Anaesth&amp;title=Analgesic%20use%20and%20associated%20adverse%20events%20in%20patients%20with%20chronic%20kidney%20disease:%20a%20systematic%20review%20and%20meta-analysis&amp;author=E.%20Lambourg&amp;author=L.%20Colvin&amp;author=G.%20Guthrie&amp;author=H.%20Walker&amp;author=S.%20Bell&amp;volume=128&amp;issue=3&amp;pages=546-561&amp;pmid=34763813&amp;doi=10.1016/j.bja.2021.08.035&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476623">
<span class="label">64.</span><cite>Safe use of opioids in chronic kidney disease and hemodialysis patients: tips and tricks for non-pain specialists. Coluzzi F., Caputi F. F., Billeci D.., et al.  2020Ther Clin Risk Manag. 16:821–837. doi: 10.2147/TCRM.S262843. <a href="https://doi.org/10.2147/TCRM.S262843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.2147/TCRM.S262843</a></cite> [<a href="https://doi.org/10.2147/TCRM.S262843" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC7490082/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/32982255/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Ther%20Clin%20Risk%20Manag&amp;title=Safe%20use%20of%20opioids%20in%20chronic%20kidney%20disease%20and%20hemodialysis%20patients:%20tips%20and%20tricks%20for%20non-pain%20specialists&amp;author=F.%20Coluzzi&amp;author=F.%20F.%20Caputi&amp;author=D..%20Billeci&amp;volume=16&amp;pages=821-837&amp;pmid=32982255&amp;doi=10.2147/TCRM.S262843&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476624">
<span class="label">65.</span><cite>Prescription opioid use before and after kidney transplant: implications for posttransplant outcomes. Lentine K. L., Lam N. N., Naik A. S.., et al.  2018Am J Transplant. 18(12):2987–2999. doi: 10.1111/ajt.14714. <a href="https://doi.org/10.1111/ajt.14714" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1111/ajt.14714</a></cite> [<a href="https://doi.org/10.1111/ajt.14714" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC6119653/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/29498196/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Prescription%20opioid%20use%20before%20and%20after%20kidney%20transplant:%20implications%20for%20posttransplant%20outcomes&amp;author=K.%20L.%20Lentine&amp;author=N.%20N.%20Lam&amp;author=A.%20S..%20Naik&amp;volume=18&amp;issue=12&amp;pages=2987-2999&amp;pmid=29498196&amp;doi=10.1111/ajt.14714&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476625">
<span class="label">66.</span><cite>Cost of treating arthritis and NSAID-related gastrointestinal side-effects. Bloom B. S. 1988Aliment Pharmacol Ther. 2(suppl 1):131–138. doi: 10.1111/j.1365-2036.1988.tb00772.x. <a href="https://doi.org/10.1111/j.1365-2036.1988.tb00772.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1111/j.1365-2036.1988.tb00772.x</a></cite> [<a href="https://doi.org/10.1111/j.1365-2036.1988.tb00772.x" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/2979281/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Aliment%20Pharmacol%20Ther&amp;title=Cost%20of%20treating%20arthritis%20and%20NSAID-related%20gastrointestinal%20side-effects&amp;author=B.%20S.%20Bloom&amp;volume=2&amp;issue=suppl%201&amp;pages=131-138&amp;pmid=2979281&amp;doi=10.1111/j.1365-2036.1988.tb00772.x&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476631">
<span class="label">67.</span><cite>Management of acute renal failure. Fry A.C., Farrington K. 2006Postgrad Med J. 82(964):106–116. doi: 10.1136/pgmj.2005.038588. <a href="https://doi.org/10.1136/pgmj.2005.038588" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1136/pgmj.2005.038588</a></cite> [<a href="https://doi.org/10.1136/pgmj.2005.038588" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="/articles/PMC2596697/" class="usa-link">PMC free article</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/16461473/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Postgrad%20Med%20J&amp;title=Management%20of%20acute%20renal%20failure&amp;author=A.C.%20Fry&amp;author=K.%20Farrington&amp;volume=82&amp;issue=964&amp;pages=106-116&amp;pmid=16461473&amp;doi=10.1136/pgmj.2005.038588&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476632">
<span class="label">68.</span><cite>Vital signs: health disparities in hemodialysis-associated staphylococcus aureus bloodstream infections–United States, 2017-2020. Rha B., See I., Dunham L.., et al.  2023Am J Transplant. 23(5):676–681. doi: 10.1016/j.ajt.2023.04.001. <a href="https://doi.org/10.1016/j.ajt.2023.04.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1016/j.ajt.2023.04.001</a></cite> [<a href="https://doi.org/10.1016/j.ajt.2023.04.001" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/37130620/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=Am%20J%20Transplant&amp;title=Vital%20signs:%20health%20disparities%20in%20hemodialysis-associated%20staphylococcus%20aureus%20bloodstream%20infections%E2%80%93United%20States,%202017-2020&amp;author=B.%20Rha&amp;author=I.%20See&amp;author=L..%20Dunham&amp;volume=23&amp;issue=5&amp;pages=676-681&amp;pmid=37130620&amp;doi=10.1016/j.ajt.2023.04.001&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
<li id="ref-476643">
<span class="label">69.</span><cite>What is value in health care? Porter M. E. 2010N Engl J Med. 363(26):2477–2481. doi: 10.1056/NEJMp1011024. <a href="https://doi.org/10.1056/NEJMp1011024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">https://doi.org/10.1056/NEJMp1011024</a></cite> [<a href="https://doi.org/10.1056/NEJMp1011024" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">DOI</a>] [<a href="https://pubmed.ncbi.nlm.nih.gov/21142528/" class="usa-link">PubMed</a>] [<a href="https://scholar.google.com/scholar_lookup?journal=N%20Engl%20J%20Med&amp;title=What%20is%20value%20in%20health%20care?&amp;author=M.%20E.%20Porter&amp;volume=363&amp;issue=26&amp;pages=2477-2481&amp;pmid=21142528&amp;doi=10.1056/NEJMp1011024&amp;" class="usa-link usa-link--external" data-ga-action="click_feat_suppl" target="_blank" rel="noopener noreferrer">Google Scholar</a>]</li>
</ul></section></section><section id="_ad93_" lang="en" class="associated-data"><h2 class="pmc_sec_title">Associated Data</h2>
<p class="font-secondary"><em>This section collects any data citations, data availability statements, or supplementary materials included in this article.</em></p>
<section id="_adsm93_" lang="en" class="supplementary-materials"><h3 class="pmc_sec_title">Supplementary Materials</h3>
<section class="sm xbox font-sm" id="db_ds_supplementary-material1_reqid_"><div class="caption p"><span>Online Supplementary Material</span></div>
<div class="media p"><div class="caption">
<a href="/articles/instance/12333935/bin/jheor_2025_12_2_142078_297142.pdf" data-ga-action="click_feat_suppl" class="usa-link">jheor_2025_12_2_142078_297142.pdf</a><sup> (1MB, pdf) </sup>
</div></div></section></section></section></section><footer class="p courtesy-note font-secondary font-sm text-center"><hr class="headless">
<p>Articles from Journal of Health Economics and Outcomes Research are provided here courtesy of <strong>Columbia Data Analytics, LLC</strong></p></footer></section></article>

                      

                    </main>
                </div>
            </div>
        </div>

        



<!-- Secondary navigation placeholder -->
<div class="pmc-sidenav desktop:grid-col-4 display-flex">
    <section class="pmc-sidenav__container" aria-label="Article resources and navigation">
        <button type="button" class="usa-button pmc-sidenav__container__close usa-button--unstyled">
            <img src="/static/img/usa-icons/close.svg" role="img" alt="Close" />
        </button>
    <div class="display-none desktop:display-block">
       <section class="margin-top-4 desktop:margin-top-0">
              <h2 class="margin-top-0">ACTIONS</h2>
           <ul class="usa-list usa-list--unstyled usa-list--actions">
               
               <li>
                     <a
                             href="https://doi.org/10.36469/001c.142078"
                             class="usa-button usa-button--outline width-24 font-xs display-inline-flex flex-align-center flex-justify-start padding-left-1"
                             target="_blank"
                             rel="noreferrer noopener"
                             data-ga-category="actions"
                             data-ga-action="click"
                             data-ga-label="publisher_link_desktop"
                     >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#launch"></use>
                         </svg>
                         <span class="display-inline-flex flex-justify-center flex-1 padding-right-2">View on publisher site</span>
                     </a>
               </li>
               
               
               <li>
                    <a
                            href="pdf/jheor_2025_12_2_142078.pdf"
                            class="usa-button usa-button--outline width-24 display-inline-flex flex-align-center flex-justify-start padding-left-1"
                            data-ga-category="actions"
                            data-ga-action="click"
                            data-ga-label="pdf_download_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#file_download"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1">PDF (1.6 MB)</span>
                    </a>
               </li>
               
                
               <li>
                   <button role="button" class="usa-button width-24 citation-dialog-trigger display-inline-flex flex-align-center flex-justify-start padding-left-1"
                        aria-label="Open dialog with citation text in different styles"
                        data-ga-category="actions"
                        data-ga-action="open"
                        data-ga-label="cite_desktop"
                        data-all-citations-url="/resources/citations/12333935/"
                        data-citation-style="nlm"
                        data-download-format-link="/resources/citations/12333935/export/"
                    >
                        <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#format_quote"></use>
                        </svg>
                       <span class="display-inline-flex flex-justify-center flex-1 button-label">Cite</span>
                    </button>
               </li>
                
               <li>

                        <button class="usa-button width-24 collections-dialog-trigger collections-button display-inline-flex flex-align-center flex-justify-start padding-left-1 collections-button-empty"
                              aria-label="Save article in MyNCBI collections."
                              data-ga-category="actions"
                              data-ga-action="click"
                              data-ga-label="collections_button_desktop"
                              data-collections-open-dialog-enabled="false"
                              data-collections-open-dialog-url="https://account.ncbi.nlm.nih.gov/?back_url=https%3A%2F%2Fpmc.ncbi.nlm.nih.gov%2Farticles%2FPMC12333935%2F%3Freport%3Dclassic%23open-collections-dialog"
                              data-in-collections="false">
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-full" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-full.svg#icon"></use>
                            </svg>
                            <svg class="usa-icon width-3 height-3 usa-icon--bookmark-empty" aria-hidden="true" focusable="false" role="img" hidden>
                                <use xlink:href="/static/img/action-bookmark-empty.svg#icon"></use>
                            </svg>
                            <span class="display-inline-flex flex-justify-center flex-1">Collections</span>
                       </button>
               </li>
               <li class="pmc-permalink">
                    <button
                            type="button"
                            class="usa-button width-24 display-inline-flex flex-align-center flex-justify padding-left-1 shadow-none"
                            aria-label="Show article permalink"
                            aria-expanded="false"
                            aria-haspopup="true"
                            data-ga-category="actions"
                            data-ga-action="open"
                            data-ga-label="permalink_desktop"
                    >
                         <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img" hidden>
                            <use xlink:href="/static/img/sprite.svg#share"></use>
                        </svg>
                        <span class="display-inline-flex flex-justify-center flex-1 button-label">Permalink</span>
                    </button>
                   

<div class="pmc-permalink__dropdown" hidden>
    <div class="pmc-permalink__dropdown__container">
          <h2 class="usa-modal__heading margin-top-0 margin-bottom-2 text-uppercase font-sans-xs">PERMALINK</h2>
          <div class="pmc-permalink__dropdown__content">
              <input type="text" class="usa-input" value="https://pmc.ncbi.nlm.nih.gov/articles/PMC12333935/" aria-label="Article permalink">
              <button class="usa-button display-inline-flex pmc-permalink__dropdown__copy__btn margin-right-0" title="Copy article permalink" data-ga-category="save_share" data-ga-action="link" data-ga-label="copy_link">
                  <svg class="usa-icon" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#content_copy"></use>
                  </svg>
                  <span class="margin-left-1">Copy</span>
              </button>
          </div>
    </div>
</div>
               </li>
           </ul>
       </section>
     </div>

        <section class="pmc-resources margin-top-6 desktop:margin-top-4" data-page-path="/articles/PMC12333935/">
            <h2 class="margin-top-0">RESOURCES</h2>
            
                <div class="usa-accordion usa-accordion--multiselectable" data-allow-multiple>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-similar-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_similar_articles"
                        data-ga-label="/articles/PMC12333935/"
                        data-action-open="open_similar_articles"
                        data-action-close="close_similar_articles"
                        >
                            Similar articles
                        </button>
                    </h3>
                    <div
                            id="resources-similar-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/similar-article-links/40787087/"
                            
                    >
                        
                    </div>
                    <h3 class="usa-accordion__heading">
                        <button
                        type="button"
                        class="usa-accordion__button"
                        aria-expanded="false"
                        aria-controls="resources-cited-by-other-articles"
                        data-ga-category="resources_accordion"
                        data-ga-action="open_cited_by"
                        data-ga-label="/articles/PMC12333935/"
                        data-action-open="open_cited_by"
                        data-action-close="close_cited_by"
                        >
                             Cited by other articles
                        </button>
                    </h3>
                    <div
                            id="resources-cited-by-other-articles"
                            class="usa-accordion__content usa-prose"
                            
                                data-source-url="/resources/cited-by-links/40787087/"
                            
                    >
                          
                    </div>
                    
                        <h3 class="usa-accordion__heading">
                            <button
                            type="button"
                            class="usa-accordion__button"
                            aria-expanded="false"
                            aria-controls="resources-links-to-ncbi-databases"
                            data-ga-category="resources_accordion"
                            data-ga-action="open_NCBI_links"
                            data-ga-label="/articles/PMC12333935/"
                            data-action-open="open_NCBI_links"
                            data-action-close="close_NCBI_link"
                            >
                                 Links to NCBI Databases
                            </button>
                        </h3>
                        <div
                                id="resources-links-to-ncbi-databases"
                                class="usa-accordion__content usa-prose"
                                data-source-url="/resources/db-links/12333935/"
                        >
                        </div>
                    
                    
                </div>
            
        </section>


        <section
        class="usa-in-page-nav usa-in-page-nav--wide margin-top-6 desktop:margin-top-4"
        data-title-text="On this page"
        data-title-heading-level="h2"
        data-scroll-offset="0"
        data-root-margin="-10% 0px -80% 0px"
        data-main-content-selector="main"
        data-threshold="1"
        hidden
        ></section>
    </section>
</div>


        

<div class="overlay" role="dialog" aria-label="Citation Dialog" hidden>
    <div class="dialog citation-dialog" aria-hidden="true">
        <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
            <h2 class="usa-modal__heading margin-0">Cite</h2>
             <button type="button" class="usa-button usa-button--unstyled close-overlay text-black width-auto"  tabindex="1">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#close"></use>
                </svg>
             </button>
        </div>

        

<div class="citation-text-block">
  <div class="citation-text margin-bottom-2"></div>
  <ul class="usa-list usa-list--unstyled display-inline-flex flex-justify width-full flex-align-center">
      <li>
        <button
          class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center copy-button dialog-focus"
          data-ga-category="save_share"
          data-ga-action="cite"
          data-ga-label="copy"
          tabindex="2">
            <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                <use xlink:href="/static/img/sprite.svg#content_copy"></use>
            </svg>
            <span>Copy</span>
        </button>
      </li>
      <li>
          <a
              href="#"
              role="button"
              class="usa-button usa-button--unstyled text-no-underline display-flex flex-align-center export-button"
              data-ga-category="save_share"
              data-ga-action="cite"
              data-ga-label="download"
              title="Download a file for external citation management software"
              tabindex="3">
                <svg class="usa-icon width-3 height-3" aria-hidden="true" focusable="false" role="img">
                    <use xlink:href="/static/img/sprite.svg#file_download"></use>
                </svg>
                <span class="display-none mobile-lg:display-inline">Download .nbib</span>
                <span class="display-inline mobile-lg:display-none">.nbib</span>
            </a>
      </li>
      <li>
          

<div class="display-inline-flex flex-align-center">
  <label class="usa-label margin-top-0">Format:</label>
  <select aria-label="Format" class="usa-select citation-style-selector padding-1 margin-top-0 border-0 padding-right-4" tabindex="4" >
    
      <option data-style-url-name="ama"
              value="AMA"
              >
        AMA
      </option>
    
      <option data-style-url-name="apa"
              value="APA"
              >
        APA
      </option>
    
      <option data-style-url-name="mla"
              value="MLA"
              >
        MLA
      </option>
    
      <option data-style-url-name="nlm"
              value="NLM"
              selected="selected">
        NLM
      </option>
    
  </select>
</div>
      </li>
  </ul>
</div>
    </div>
</div>

        <div class="overlay" role="dialog" hidden>
  <div id="collections-action-dialog" class="dialog collections-dialog" aria-hidden="true">
   <div class="display-inline-flex flex-align-center flex-justify width-full margin-bottom-2">
        <h2 class="usa-modal__heading margin-0">Add to Collections</h2>
    </div>
    <div class="collections-action-panel action-panel">
      


<form id="collections-action-dialog-form"
      class="usa-form maxw-full collections-action-panel-form action-panel-content action-form action-panel-smaller-selectors"
      data-existing-collections-url="/list-existing-collections/"
      data-add-to-existing-collection-url="/add-to-existing-collection/"
      data-create-and-add-to-new-collection-url="/create-and-add-to-new-collection/"
      data-myncbi-max-collection-name-length="100"
      data-collections-root-url="https://www.ncbi.nlm.nih.gov/myncbi/collections/">

    <input type="hidden" name="csrfmiddlewaretoken" value="cm08Im147QIur0jO12KBM0ezCjHsuZtCnJzj7qEieMHiZIeXblp5gevYyU593ga1">

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-new"
            class="usa-radio__input usa-radio__input--tile collections-new  margin-top-0"
            name="collections"
            value="new"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_new" />
            <label class="usa-radio__label" for="collections-action-dialog-new">Create a new collection</label>
        </div>
        <div class="usa-radio">
            <input type="radio"
            id="collections-action-dialog-existing"
            class="usa-radio__input usa-radio__input--tile collections-existing"
            name="collections"
            value="existing"
            checked="true"
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="collections_radio_existing" />
            <label class="usa-radio__label" for="collections-action-dialog-existing">Add to an existing collection</label>
        </div>
    </fieldset>

    <fieldset class="usa-fieldset margin-bottom-2">
        <div class="action-panel-control-wrap new-collections-controls">
           <label for="collections-action-dialog-add-to-new" class="usa-label margin-top-0">
                Name your collection
               <abbr title="required" class="usa-hint usa-hint--required text-no-underline">*</abbr>
          </label>
          <input
            type="text"
            name="add-to-new-collection"
            id="collections-action-dialog-add-to-new"
            class="usa-input collections-action-add-to-new"
            pattern="[^&quot;&amp;=&lt;&gt;/]*" title="The following characters are not allowed in the Name field: &quot;&amp;=&lt;&gt;/"
            maxlength=""
            data-ga-category="collections_button"
            data-ga-action="create_collection"
            data-ga-label="non_favorties_collection"
            required
          />
        </div>
        <div class="action-panel-control-wrap existing-collections-controls">
             <label for="collections-action-dialog-add-to-existing" class="usa-label margin-top-0">
                Choose a collection
              </label>
              <select id="collections-action-dialog-add-to-existing"
                      class="usa-select collections-action-add-to-existing"
                      data-ga-category="collections_button"
                      data-ga-action="select_collection"
                      data-ga-label="($('.collections-action-add-to-existing').val() === 'Favorites') ? 'Favorites' : 'non_favorites_collection'">
              </select>
              <div class="collections-retry-load-on-error usa-input-error-message selection-validation-message">
                Unable to load your collection due to an error<br>
                <a href="#">Please try again</a>
              </div>
        </div>
    </fieldset>

    <div class="display-inline-flex">
        <button class="usa-button margin-top-0 action-panel-submit"
            type="submit"
            data-loading-label="Adding..."
            data-pinger-ignore
            data-ga-category="collections_button"
            data-ga-action="click"
            data-ga-label="add">
          Add
        </button>
        <button class="usa-button usa-button--outline margin-top-0 action-panel-cancel"
                aria-label="Close 'Add to Collections' panel"
                ref="linksrc=close_collections_panel"
                data-ga-category="collections_button"
                data-ga-action="click"
                data-ga-label="cancel">
          Cancel
        </button>
    </div>
</form>
    </div>
  </div>
</div>

        

      </div>
    </div>
  </div>



        
    
    

<footer class="ncbi-footer ncbi-dark-background " >
    
        <div class="ncbi-footer__icon-section">
            <div class="ncbi-footer__social-header">
                Follow NCBI
            </div>

            <div class="grid-container ncbi-footer__ncbi-social-icons-container">
                
                    <a href="https://twitter.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="40"
                             height="40"
                             viewBox="0 0 40 40"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on X (formerly known as Twitter)</span>
                    </a>
                

                
                    <a href="https://www.facebook.com/ncbi.nlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="16"
                             height="29"
                             focusable="false"
                             aria-hidden="true"
                             viewBox="0 0 16 29"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg">
                            <path d="M3.8809 21.4002C3.8809 19.0932 3.8809 16.7876 3.8809 14.478C3.8809 14.2117 3.80103 14.1452 3.54278 14.1492C2.53372 14.1638 1.52334 14.1492 0.514288 14.1598C0.302626 14.1598 0.248047 14.0972 0.248047 13.8936C0.256034 12.4585 0.256034 11.0239 0.248047 9.58978C0.248047 9.37013 0.302626 9.30224 0.528931 9.3049C1.53798 9.31688 2.54837 9.3049 3.55742 9.31555C3.80103 9.31555 3.8809 9.26097 3.87957 9.00272C3.87158 8.00565 3.85428 7.00592 3.90753 6.00884C3.97142 4.83339 4.31487 3.73115 5.04437 2.78467C5.93095 1.63318 7.15699 1.09005 8.56141 0.967577C10.5582 0.79319 12.555 0.982221 14.5518 0.927641C14.7102 0.927641 14.7462 0.99287 14.7449 1.13664C14.7449 2.581 14.7449 4.02668 14.7449 5.47104C14.7449 5.67604 14.6517 5.68669 14.4946 5.68669C13.4523 5.68669 12.4113 5.68669 11.3703 5.68669C10.3506 5.68669 9.92057 6.10868 9.90593 7.13904C9.89661 7.7647 9.91525 8.39303 9.89794 9.01869C9.88995 9.26364 9.96583 9.31822 10.2015 9.31688C11.7204 9.30623 13.2393 9.31688 14.7595 9.3049C15.0257 9.3049 15.0723 9.3728 15.0444 9.62439C14.89 10.9849 14.7515 12.3467 14.6144 13.7085C14.5691 14.1571 14.5785 14.1585 14.1458 14.1585C12.8386 14.1585 11.5313 14.1665 10.2254 14.1518C9.95119 14.1518 9.89794 14.2317 9.89794 14.4899C9.90593 19.0799 9.89794 23.6752 9.91125 28.2612C9.91125 28.5674 9.8407 28.646 9.53186 28.6433C7.77866 28.6273 6.02414 28.6366 4.27094 28.634C3.82499 28.634 3.87158 28.6992 3.87158 28.22C3.87602 25.9472 3.87913 23.6739 3.8809 21.4002Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on Facebook</span>
                    </a>
                

                
                    <a href="https://www.linkedin.com/company/ncbinlm"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="25"
                             height="23"
                             viewBox="0 0 26 24"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M14.6983 9.98423C15.6302 9.24808 16.5926 8.74754 17.6762 8.51991C19.673 8.09126 21.554 8.30824 23.1262 9.7526C24.2351 10.7723 24.7529 12.1115 25.0165 13.5612C25.1486 14.3363 25.2105 15.1218 25.2015 15.9081C25.2015 18.3043 25.2015 20.6898 25.2082 23.0806C25.2082 23.3468 25.1549 23.444 24.8621 23.4414C23.1297 23.4272 21.3992 23.4272 19.6704 23.4414C19.4041 23.4414 19.3429 23.3588 19.3442 23.1019C19.3535 20.5194 19.3442 17.9368 19.3442 15.3543C19.3442 14.0005 18.3258 12.9448 17.0266 12.9488C15.7273 12.9528 14.6983 14.0071 14.6983 15.361C14.6983 17.9328 14.6917 20.5047 14.6983 23.0753C14.6983 23.3708 14.6198 23.444 14.3296 23.4427C12.6185 23.4294 10.9079 23.4294 9.19779 23.4427C8.93155 23.4427 8.86099 23.3735 8.86232 23.1086C8.8783 19.7619 8.88628 16.4144 8.88628 13.066C8.88628 11.5688 8.87874 10.0708 8.86365 8.57182C8.86365 8.3575 8.90758 8.27896 9.14054 8.28029C10.9048 8.29094 12.6687 8.29094 14.4321 8.28029C14.6464 8.28029 14.6983 8.34818 14.6983 8.54653C14.6903 9.00047 14.6983 9.45441 14.6983 9.98423Z">
                            </path>
                            <path d="M6.55316 15.8443C6.55316 18.2564 6.55316 20.6699 6.55316 23.082C6.55316 23.3629 6.48127 23.4388 6.19906 23.4374C4.47737 23.4241 2.75568 23.4241 1.03399 23.4374C0.767751 23.4374 0.69986 23.3629 0.701191 23.1006C0.709178 18.2648 0.709178 13.4281 0.701191 8.59053C0.701191 8.34026 0.765089 8.27237 1.01669 8.2737C2.74991 8.28435 4.48048 8.28435 6.20838 8.2737C6.47462 8.2737 6.5465 8.33627 6.54517 8.6065C6.54783 11.0186 6.55316 13.4308 6.55316 15.8443Z">
                            </path>
                            <path d="M3.65878 0.243898C5.36804 0.243898 6.58743 1.45529 6.58743 3.1406C6.58743 4.75801 5.32145 5.95742 3.60819 5.96807C3.22177 5.97614 2.83768 5.90639 2.47877 5.76299C2.11985 5.61959 1.79344 5.40546 1.51897 5.13334C1.24449 4.86123 1.02755 4.53668 0.881058 4.17902C0.734563 3.82136 0.661505 3.43788 0.666231 3.05141C0.67555 1.42601 1.9362 0.242566 3.65878 0.243898Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on LinkedIn</span>
                    </a>
                

                
                    <a href="https://github.com/ncbi"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="28"
                             height="27"
                             viewBox="0 0 28 28"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M16.7228 20.6334C17.5057 20.5527 18.2786 20.3944 19.0301 20.1608C21.3108 19.4193 22.5822 17.8259 22.963 15.4909C23.1228 14.5112 23.1814 13.5287 22.9883 12.5437C22.8106 11.6423 22.4013 10.8028 21.8007 10.1076C21.7526 10.0605 21.7197 10 21.7064 9.934C21.6931 9.86799 21.7 9.79952 21.7262 9.73748C22.0856 8.6206 21.9711 7.51969 21.601 6.42677C21.582 6.3497 21.5345 6.2827 21.468 6.23923C21.4016 6.19577 21.3211 6.17906 21.2429 6.19248C20.7329 6.21649 20.2313 6.33051 19.7611 6.52928C19.1103 6.7908 18.4899 7.12198 17.9104 7.51703C17.84 7.56996 17.7581 7.60551 17.6713 7.62078C17.5846 7.63605 17.4954 7.6306 17.4112 7.60489C15.2596 7.05882 13.0054 7.06203 10.8554 7.61421C10.7806 7.63586 10.7018 7.63967 10.6253 7.62534C10.5487 7.611 10.4766 7.57892 10.4148 7.53167C9.64788 7.03247 8.85171 6.58918 7.96368 6.33359C7.65781 6.24338 7.34123 6.19458 7.02239 6.18849C6.94879 6.17986 6.87462 6.19893 6.81432 6.242C6.75402 6.28507 6.71191 6.34904 6.69621 6.42145C6.32342 7.51437 6.2209 8.61527 6.56307 9.73348C6.59635 9.84264 6.64694 9.93316 6.54177 10.0516C5.47666 11.2604 5.09988 12.6834 5.19574 14.2676C5.2663 15.4244 5.46201 16.5466 6.01454 17.5769C6.84399 19.1171 8.21664 19.9119 9.85158 20.3352C10.3938 20.4706 10.9444 20.5698 11.4998 20.632C11.5384 20.7492 11.4506 20.7798 11.408 20.8291C11.1734 21.1179 10.9894 21.4441 10.8634 21.7942C10.7622 22.0458 10.8315 22.4039 10.6065 22.5516C10.263 22.7766 9.83827 22.8485 9.42421 22.8871C8.17936 23.0056 7.26471 22.4877 6.6283 21.4348C6.25552 20.8184 5.76956 20.3325 5.08523 20.0663C4.76981 19.9325 4.42139 19.8967 4.08537 19.9638C3.7898 20.029 3.73788 20.1901 3.93891 20.4111C4.03639 20.5234 4.14989 20.6207 4.27575 20.6999C4.9796 21.1318 5.51717 21.7884 5.80152 22.5636C6.37002 23.9973 7.48039 24.5697 8.93825 24.6323C9.43741 24.6575 9.93768 24.615 10.4254 24.5058C10.5892 24.4672 10.6531 24.4872 10.6517 24.6762C10.6451 25.4936 10.6637 26.3123 10.6517 27.131C10.6517 27.6635 10.1684 27.9297 9.58663 27.7393C8.17396 27.2671 6.84977 26.5631 5.66838 25.656C2.59555 23.2891 0.720966 20.1861 0.217704 16.3376C-0.357453 11.9127 0.911353 8.00824 3.98551 4.73881C6.11909 2.42656 8.99932 0.939975 12.1203 0.540191C16.5351 -0.0601815 20.4347 1.14323 23.7232 4.16373C26.2449 6.47869 27.724 9.37672 28.1048 12.7726C28.5828 17.0325 27.3686 20.7945 24.4768 23.9827C22.9762 25.6323 21.0956 26.8908 18.9982 27.6488C18.8783 27.6927 18.7585 27.738 18.636 27.7726C18.0356 27.9404 17.6189 27.6395 17.6189 27.0098C17.6189 25.7452 17.6308 24.4806 17.6295 23.2159C17.6329 22.9506 17.6128 22.6856 17.5696 22.4238C17.4325 21.6664 17.3419 21.484 16.7228 20.6334Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI on GitHub</span>
                    </a>
                

                
                    <a href="https://ncbiinsights.ncbi.nlm.nih.gov/"
                       class="ncbi-footer__social-icon ncbi-footer__social-icon--gray"
                       target="_blank"
                       rel="noreferrer noopener">
                        <svg width="26"
                             height="26"
                             viewBox="0 0 27 27"
                             fill="none"
                             xmlns="http://www.w3.org/2000/svg"
                             focusable="false"
                             aria-hidden="true">
                            <path d="M23.7778 26.4574C23.1354 26.3913 22.0856 26.8024 21.636 26.3087C21.212 25.8444 21.4359 24.8111 21.324 24.0347C19.9933 14.8323 14.8727 8.80132 6.09057 5.85008C4.37689 5.28406 2.58381 4.99533 0.779072 4.99481C0.202773 4.99481 -0.0229751 4.83146 0.00455514 4.21479C0.0660406 3.08627 0.0660406 1.95525 0.00455514 0.826734C-0.0413285 0.0815827 0.259669 -0.0193618 0.896534 0.00266238C6.96236 0.222904 12.3693 2.24179 16.9889 6.16209C22.9794 11.2478 26.1271 17.7688 26.4372 25.648C26.4629 26.294 26.3179 26.5271 25.6609 26.4684C25.0827 26.417 24.4991 26.4574 23.7778 26.4574Z">
                            </path>
                            <path d="M14.8265 26.441C14.0924 26.441 13.2371 26.6795 12.6626 26.3786C12.0092 26.0372 12.3781 25.0644 12.246 24.378C11.1154 18.5324 6.6849 14.5497 0.74755 14.1001C0.217135 14.0615 -0.0104482 13.9422 0.0134113 13.3659C0.0519536 12.1454 0.0482829 10.9213 0.0134113 9.69524C-0.00127145 9.14464 0.196946 9.03268 0.703502 9.04736C9.21217 9.27128 16.5994 16.2511 17.2804 24.7231C17.418 26.4446 17.418 26.4446 15.6579 26.4446H14.832L14.8265 26.441Z">
                            </path>
                            <path d="M3.58928 26.4555C2.64447 26.4618 1.73584 26.0925 1.06329 25.4289C0.39073 24.7653 0.00933763 23.8617 0.0030097 22.9169C-0.00331824 21.9721 0.365937 21.0635 1.02954 20.3909C1.69315 19.7184 2.59675 19.337 3.54156 19.3306C4.48637 19.3243 5.39499 19.6936 6.06755 20.3572C6.7401 21.0208 7.1215 21.9244 7.12782 22.8692C7.13415 23.814 6.7649 24.7226 6.10129 25.3952C5.43768 26.0677 4.53409 26.4491 3.58928 26.4555Z">
                            </path>
                        </svg>
                        <span class="usa-sr-only">NCBI RSS feed</span>
                    </a>
                
            </div>
        </div>
    

    <div data-testid="gridContainer"
         class="grid-container ncbi-footer__container">
        <div class="grid-row ncbi-footer__main-content-container"
             data-testid="grid">
            
                <div class="ncbi-footer__column">
                    
                        <p class="ncbi-footer__circled-icons-heading">
                            Connect with NLM
                        </p>
                    

                    <div class="ncbi-footer__circled-icons-list">
                        
                            <a href=https://twitter.com/nlm_nih class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="32"
                                     height="32"
                                     viewBox="0 0 40 40"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="m6.067 8 10.81 13.9L6 33.2h4.2l8.4-9.1 7.068 9.1H34L22.8 18.5 31.9 8h-3.5l-7.7 8.4L14.401 8H6.067Zm3.6 1.734h3.266l16.8 21.732H26.57L9.668 9.734Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on X (formerly known as Twitter)</span>
                            </a>
                        

                        
                            <a href=https://www.facebook.com/nationallibraryofmedicine class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="13"
                                     height="24"
                                     viewBox="0 0 13 24"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M4.11371 23.1369C4.11371 23.082 4.11371 23.0294 4.11371 22.9745V12.9411H0.817305C0.6709 12.9411 0.670898 12.9411 0.670898 12.8016C0.670898 11.564 0.670898 10.3287 0.670898 9.09341C0.670898 8.97903 0.705213 8.95158 0.815017 8.95158C1.8673 8.95158 2.91959 8.95158 3.97417 8.95158H4.12057V8.83263C4.12057 7.8055 4.12057 6.7738 4.12057 5.74897C4.1264 4.92595 4.31387 4.11437 4.66959 3.37217C5.12916 2.38246 5.94651 1.60353 6.95717 1.1921C7.64827 0.905008 8.3913 0.764035 9.13953 0.778051C10.0019 0.791777 10.8644 0.830666 11.7268 0.860404C11.8869 0.860404 12.047 0.894717 12.2072 0.90158C12.2964 0.90158 12.3261 0.940469 12.3261 1.02968C12.3261 1.5421 12.3261 2.05452 12.3261 2.56465C12.3261 3.16857 12.3261 3.7725 12.3261 4.37642C12.3261 4.48165 12.2964 4.51367 12.1912 4.51138C11.5369 4.51138 10.8804 4.51138 10.2261 4.51138C9.92772 4.51814 9.63058 4.5526 9.33855 4.61433C9.08125 4.6617 8.84537 4.78881 8.66431 4.97766C8.48326 5.16652 8.3662 5.40755 8.32972 5.66661C8.28476 5.89271 8.26027 6.1224 8.25652 6.35289C8.25652 7.19014 8.25652 8.02969 8.25652 8.86923C8.25652 8.89439 8.25652 8.91955 8.25652 8.95615H12.0219C12.1797 8.95615 12.182 8.95616 12.1614 9.10714C12.0768 9.76596 11.9876 10.4248 11.9029 11.0813C11.8312 11.6319 11.7626 12.1824 11.697 12.733C11.6719 12.9434 11.6787 12.9434 11.4683 12.9434H8.26338V22.899C8.26338 22.979 8.26338 23.0591 8.26338 23.1392L4.11371 23.1369Z">
                                    </path>
                                </svg>
                                <span class="usa-sr-only">NLM on Facebook</span>
                            </a>
                        

                        
                            <a href=https://www.youtube.com/user/NLMNIH class="ncbi-footer__social-icon ncbi-footer__social-icon--circled" target="_blank" rel="noreferrer noopener">
                                <svg width="21"
                                     height="15"
                                     viewBox="0 0 21 15"
                                     fill="none"
                                     xmlns="http://www.w3.org/2000/svg"
                                     focusable="false"
                                     aria-hidden="true">
                                    <path d="M19.2561 1.47914C18.9016 1.15888 18.5699 0.957569 17.2271 0.834039C15.5503 0.678484 13.2787 0.655608 11.563 0.65332H9.43556C7.71987 0.65332 5.4483 0.678484 3.77151 0.834039C2.43098 0.957569 2.097 1.15888 1.74242 1.47914C0.813665 2.32097 0.619221 4.62685 0.598633 6.89384C0.598633 7.31781 0.598633 7.74101 0.598633 8.16345C0.626084 10.4121 0.827391 12.686 1.74242 13.521C2.097 13.8412 2.4287 14.0425 3.77151 14.1661C5.4483 14.3216 7.71987 14.3445 9.43556 14.3468H11.563C13.2787 14.3468 15.5503 14.3216 17.2271 14.1661C18.5676 14.0425 18.9016 13.8412 19.2561 13.521C20.1712 12.6929 20.3725 10.451 20.3999 8.22064C20.3999 7.74025 20.3999 7.25986 20.3999 6.77946C20.3725 4.54907 20.1689 2.30724 19.2561 1.47914ZM8.55942 10.5311V4.65201L13.5601 7.50005L8.55942 10.5311Z"
                                          fill="white" />
                                </svg>
                                <span class="usa-sr-only">NLM on YouTube</span>
                            </a>
                        
                    </div>
                </div>
            

            
                <address class="ncbi-footer__address ncbi-footer__column">
                    
        <p>
            <a class="usa-link usa-link--external"
            href="https://www.google.com/maps/place/8600+Rockville+Pike,+Bethesda,+MD+20894/%4038.9959508,
            -77.101021,17z/data%3D!3m1!4b1!4m5!3m4!1s0x89b7c95e25765ddb%3A0x19156f88b27635b8!8m2!3d38.9959508!
            4d-77.0988323"
            rel="noopener noreferrer" target="_blank">National Library of Medicine
            <br/> 8600 Rockville Pike<br/> Bethesda, MD 20894</a>
        </p>
    
                </address>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/web_policies.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Web Policies

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nih.gov/institutes-nih/nih-office-director/office-communications-public-liaison/freedom-information-act-office" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    FOIA

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.hhs.gov/vulnerability-disclosure-policy/index.html" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS Vulnerability Disclosure

    
</a>

                        </li>
                    
                </ul>
            

            
                <ul class="usa-list usa-list--unstyled ncbi-footer__vertical-list ncbi-footer__column">
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://support.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Help

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/accessibility.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Accessibility

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__vertical-list-item">
                            








<a href="https://www.nlm.nih.gov/careers/careers.html" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    Careers

    
</a>

                        </li>
                    
                </ul>
            
        </div>

        
            <div class="grid-row grid-col-12" data-testid="grid">
                <ul class="ncbi-footer__bottom-links-list">
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nlm.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NLM

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.nih.gov/" class="usa-link  usa-link--alt ncbi-footer__link"  >
    

    NIH

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.hhs.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    HHS

    
</a>

                        </li>
                    
                        <li class="ncbi-footer__bottom-list-item">
                            








<a href="https://www.usa.gov/" class="usa-link usa-link--external usa-link--alt ncbi-footer__link" rel="noreferrer noopener" target='_blank' >
    

    USA.gov

    
</a>

                        </li>
                    
                </ul>
            </div>
        
    </div>
</footer>

    


        
        
    
  <script  type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/pinger/pinger.js"> </script>


    
        

<button class="back-to-top" data-ga-category="pagination" data-ga-action="back_to_top">
    <label>Back to Top</label>
    <svg class="usa-icon order-0" aria-hidden="true" focusable="false" role="img">
        <use xlink:href="/static/img/sprite.svg#arrow_upward"></use>
    </svg>
</button>
    


        
    
    
    
        
    <script type="application/javascript">
    window.ncbi = window.ncbi || {};
    window.ncbi.pmc = window.ncbi.pmc || {};
    window.ncbi.pmc.options = {
        logLevel: 'INFO',
        
        staticEndpoint: '/static/',
        
        citeCookieName: 'pmc-cf',
    };
</script>
    <script type="module" crossorigin="" src="/static/assets/base-370d5dd6.js"></script>
    
    <script type="text/javascript" src="https://cdn.ncbi.nlm.nih.gov/core/jquery/jquery-3.6.0.min.js">&#xA0;</script>
    <script type="text/javascript">
        jQuery.getScript("https://cdn.ncbi.nlm.nih.gov/core/alerts/alerts.js", function () {
            galert(['div.nav_and_browser', 'div.header', '#universal_header', '.usa-banner', 'body > *:nth-child(1)'])
        });
    </script>


    <script type="text/javascript">var exports = {};</script>
     <script src="/static/CACHE/js/output.13b077bc3ffd.js"></script>

    <script type="module" crossorigin="" src="/static/assets/article-917ba005.js"></script>
    
        <script type="module" crossorigin="" src="/static/assets/math-d9849939.js"></script>
    
    

    </body>
</html>
